

ECCO Guideline/Consensus Paper

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders



Fernando Magro,^{a,†} Paolo Gionchetti,^{b,†} Rami Eliakim,^{c,#} Sandro Ardizzone,^d Alessandro Armuzzi,^e Manuel Barreiro-de Acosta,^f Johan Burisch,^g Krisztina B. Gecse,^h Ailsa L. Hart,ⁱ Pieter Hindryckx,^j Cord Langner,^k Jimmy K. Limdi,^l Gianluca Pellino,^m Edyta Zagórowicz,ⁿ Tim Raine,^o Marcus Harbord,^{p,#} Florian Rieder,^q for the European Crohn's and Colitis Organisation [ECCO]

^aDepartment of Pharmacology and Therapeutics, University of Porto; MedInUP, Centre for Drug Discovery and Innovative Medicines; Centro Hospitalar São João, Porto, Portugal ^bIBD Unit, DIMEC, University of Bologna, Bologna, Italy ^cDepartment of Gastroenterology and Hepatology, Chaim Sheba Medical Center, Tel Hashomer, Israel ^dGastrointestinal Unit ASST Fatebenefratelli Sacco—University of Milan—Milan, Italy ^eIBD Unit Complesso Integrato Columbus, Gastroenterological and Endocrino-Metabolical Sciences Department, Fondazione Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore, Rome, Italy ^fDepartment of Gastroenterology, IBD Unit, University Hospital Santiago De Compostela (CHUS), A Coruña, Spain ^gDepartment of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark ^hFirst Department of Medicine, Semmelweis University, Budapest, Hungary ⁱIBD Unit, St Mark's Hospital, Middlesex, UK ^jDepartment of Gastroenterology, University Hospital of Ghent, Ghent, Belgium ^kInstitute of Pathology, Medical University of Graz, Graz, Austria ^lDepartment of Gastroenterology, Pennine Acute Hospitals NHS Trust; Institute of Inflammation and Repair, University of Manchester, Manchester, UK ^mUnit of General Surgery, Second University of Naples, Napoli, Italy ⁿMaria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Oncological Gastroenterology Warsaw; Medical Centre for Postgraduate Education, Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, Poland ^oDepartment of Medicine, University of Cambridge, Cambridge, UK ^pImperial College London; Chelsea and Westminster Hospital, London, UK ^qDepartment of Pathobiology/NC22, Lerner Research Institute; Department of Gastroenterology, Hepatology and Nutrition/A3, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

[†]These authors contributed equally to this paper.

[#]These authors acted as convenors of the Consensus.

Corresponding author: Fernando Magro, MD, PhD, Department of Gastroenterology and Pharmacology and Therapeutics, Porto Medical School, Porto University, Porto, Portugal. Email: fm@med.up.pt

This is the third European Crohn's and Colitis Organisation [ECCO] consensus guideline that addresses ulcerative colitis [UC]. It has been drafted by 28 ECCO members from 14 European countries. It is derived from and updates the previous ECCO consensus advice on UC.^{1–3} All the authors recognise and are grateful to previous ECCO members who contributed to creating the previous consensus

guidelines^{1–6} on which some of the text is based. Attention is also drawn to other ECCO consensus guidelines which have contributed to this endeavour, on extra-intestinal manifestations [EIMs],⁷ malignancy,⁸ imaging,⁹ small bowel endoscopy,¹⁰ opportunistic infections [OIs],¹¹ surgery,¹² endoscopy,¹³ pathology,¹⁴ anaemia,¹⁵ reproduction and pregnancy,¹⁶ and paediatric UC.¹⁷

The guideline has been condensed into two papers, the first detailing definitions, classification, diagnosis, imaging, pathology, and management of special situations [EIMs, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders of UC]; and the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].

The strategy to define consensus was similar to that previously described in other ECCO consensus guidelines [available at www.ecco-ibd.eu]. Briefly, an open call for participants was made, with participants selected by the Guidelines' Committee of ECCO [known as GuiCom] on the basis of their publication record and a personal statement. Working parties were established to review the consensus statements published in 2012,¹⁻³ after which a recommendation was issued on whether they required revision based upon advances in the published literature. There was agreement that extensive review of histopathology, endoscopy, OI, anaemia, EIMs, surgery, and pregnancy was not required, as these subjects are reviewed in other ECCO guidelines^{7,11-16}; rather, abbreviated text and selected statements from these guidelines specific to UC are provided. Paediatric UC is dealt with in a separate ECCO initiative¹⁷ which is currently being updated.

Provisional ECCO statements and supporting text were written following a comprehensive literature review, then refined following two voting rounds which included national representative participation by ECCO's 35 member countries. The level of evidence was graded according to the Oxford Centre for Evidence-Based Medicine [www.cebm.net]. The ECCO statements were finalised by the authors at a meeting in Barcelona in October 2015 and represent consensus with agreement of at least 80% of participants. Consensus statements are intended to be read in context with their qualifying comments and not in isolation. The supporting text was then finalised under the direction of each working group leader [FM, FC, AD, PG, FR], including an updated literature search to October 2016 of the most relevant [eight] journals, before being integrated by a consensus leader [MH]. This consensus guideline is pictorially represented within the freely available ECCO e-Guide [<http://www.e-guide.ecco-ibd.eu/>].

Section 1. Definitions

1.1. Introduction

UC is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in developed countries. Its precise aetiology is unknown, and therefore curative medical therapy is not yet available. Within Europe there is an east-west and north-south gradient, but the incidence appears to have increased in southern and eastern countries during recent years.¹⁸⁻²⁰ Patients may live with a considerable symptom burden and high risk of disability²¹ despite medical treatment.²² Clinicians must advise and treat patients on the basis of currently available information. Despite robust evidence from rigorously conducted randomised trials, the strict and somewhat necessarily restrictive inclusion and exclusion criteria in trial design may limit translation of such evidence to 'real-world' patients.

1.2. Definitions

Ulcerative colitis [UC] is a chronic inflammatory condition that causes continuous mucosal inflammation of the colon, usually without granulomas on biopsy. It affects the rectum and to a variable extent the colon in a continuous fashion, and is characterised by a relapsing and remitting course.²³ Inflammatory bowel disease unclassified [IBDU] is the term best suited for a minority of cases in which a definitive distinction between UC, Crohn's disease, or other causes of colitis cannot be made after taking into account the

Table 1.1. Distribution of UC [adapted from Silverberg et al.²³].

Term	Distribution	Description
E1	Proctitis	Involvement limited to the rectum [i.e. proximal extent of inflammation is distal to the recto-sigmoid junction]
E2	Left-sided	Involvement limited to the proportion of the colon distal to the splenic flexure [analogous to 'distal' colitis]
E3	Extensive	Involvement extends proximal to the splenic flexure, including pan-colitis

Table 1.2. Disease activity in UC [adapted from Truelove & Witts³²].

	Mild	Moderate 'in between mild and severe'	Severe
Bloody stools/day	< 4	4 or more <i>if</i>	≥ 6 <i>and</i>
Pulse	< 90 bpm	≤ 90 bpm	> 90 bpm <i>or</i>
Temperature	< 37.5°C	≤ 37.8°C	> 37.8°C <i>or</i>
Haemoglobin	> 11.5 g/dl	≥ 10.5 g/dl	< 10.5 g/dl <i>or</i>
ESR	< 20 mm/h	≤ 30 mm/h	> 30 mm/h <i>or</i>
CRP	Normal	≤ 30 mg/l	> 30 mg/l

Table 1.3. Montréal classification of disease activity in UC [adapted from Silverberg et al.²³ and Satsangi et al.²⁴].

	S0 Remission	S1 Mild	S2 Moderate	S3 Severe
Stools/day	Asymptomatic	≤ 4	> 4	≥ 6 <i>and</i>
Blood		May be present	Present	Present
Pulse		All normal	Minimal, or no signs of systemic toxicity	> 90 bpm <i>or</i>
Temperature				> 37.5°C <i>or</i>
Haemoglobin				< 10.5 g/dl <i>or</i>
ESR				> 30 mm/h

ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; bpm, beats per minute.

history, endoscopic appearance, histopathology of multiple mucosal biopsies, and appropriate radiology.^{23,24} Indeterminate colitis is a term reserved for pathologists to describe a colectomy specimen with overlapping features of UC and Crohn's disease.^{24,25} Detailed information on definitions can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{1,23,24,26-39}

Section 2. Classification

2.1. Classification according to disease extent

ECCO statement 2A

Disease extent influences treatment modality, whether oral and/or topical therapy [EL1], and determines onset and frequency of surveillance [EL2]. It is defined by the maximal macroscopic extent at colonoscopy, classified as proctitis, left-sided colitis, and extensive colitis

Extent of inflammation influences the patient's management and the choice of delivery system for a given therapy. For example, topical therapy in the form of suppositories or enemas is usually the first-line choice for proctitis and left-sided colitis, respectively, whereas oral therapy [often combined with topical therapy] is appropriate for extensive colitis. Extent of colitis influences the risk of development of dysplasia or colorectal cancer [CRC], and thus the start and the frequency of colonoscopic surveillance.⁴⁰⁻⁴²

Patients with extensive colitis have the highest risk of developing CRC, whereas those with proctitis alone have a risk similar to the general population. Patients with left-sided colitis [including procto-sigmoiditis] carry an intermediate risk; however, their risk approaches that of patients with extensive colitis as disease duration increases.⁴³⁻⁴⁶ Therefore, patients with left-sided and extensive colitis are generally advised to have surveillance colonoscopy, whereas patients with proctitis do not need such surveillance⁴⁶ [see Section 8].

It should be noted that the macroscopic extent at colonoscopy may underestimate the extent of disease as compared with histology, and biopsies are necessary to determine the full extent of colonic inflammation, providing prognostic information and risk stratification for dysplasia surveillance.^{13,47-51} Proximal extension of proctitis or left-sided colitis may occur in 20–50% of adult patients with UC.⁵²⁻⁵⁴

2.2. Classification according to disease severity

ECCO statement 2B

Disease severity influences treatment modality and route of administration [EL1]. Clinical indices of disease severity have not been adequately validated, although clinical, laboratory, imaging, and endoscopic parameters, including histopathology, impact on patients' management [EL 2]. Remission is defined as stool frequency \leq 3/day, no rectal bleeding, and normal mucosa at endoscopy [EL5]. Absence of a histological acute inflammatory infiltrate predicts quiescent course of disease [EL3]

2.2.1. Activity and pattern of disease

It should be standard practice to confirm the presence of active colitis by flexible sigmoidoscopy and biopsy before starting treatment, which may identify unexpected causes of symptoms that mimic active disease such as cytomegalovirus [CMV] colitis, rectal mucosal prolapse, Crohn's disease, malignancy, or even irritable bowel syndrome and haemorrhoidal bleeding. In addition, all patients with presumed active disease require stool cultures including *Clostridium difficile* toxin assay to exclude enteric infection. Patients with an appropriate travel history should also have stool microscopy to exclude parasitic infections.

In a population-based study from Copenhagen County, approximately 50% of patients are in clinical remission at any time during a given year.⁵⁵ However, 90% had a cumulative probability of a relapsing course after 25 years of follow-up. Disease activity in the first 2 years after diagnosis indicated [probability 70% to 80%] an increased likelihood of five consecutive years of active disease. In a Norwegian study involving 781 patients, an inverse relationship was noted between the time to first relapse and the total number of relapses over a 10-year period.⁵⁶ In the IBSEN cohort, the 10-year cumulative relapse rate was 83%, whereas patients older than 50 years had a significantly reduced relapse rate.²⁸ In clinical trials designed for the maintenance of remission in patients with clinical remission at baseline, clinical relapse rates among patients receiving placebo range from 29% to 43% at 6 months, and from 38% to 76% at 12 months.^{33,57,58} A population-based study carried out in the county of Copenhagen⁵⁹

described the outcome in 1575 patients in the first 5 years following diagnosis of UC between 1962 and 2005. In the most recent period, the percentage of patients experiencing an 'indolent' course [no relapse during the first 5 years after diagnosis] was 13%, 74% had a 'moderate' course [two or more relapses within the first 5 years, but less than every year], and 13% had an 'aggressive' course [disease activity at least every year during the first 5 years].

Microscopic involvement is also important. In quiescent UC, a chronic inflammatory cell infiltrate was present in all biopsy specimens and crypt architectural irregularities were seen in two-thirds; 52% of patients with an acute inflammatory cell infiltrate relapsed after 12 months of follow-up, compared with 25% who relapsed without such an infiltrate [$p = 0.02$]. Similarly, relapse rates were higher in those with crypt abscesses, mucin depletion, and mucosal breaks.⁶⁰ The degree of microscopic bowel inflammation is also a risk factor for CRC in patients with long-standing, extensive UC.⁴⁹

2.2.2. Choice of index

Detailed information on the choice of index can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{32,33}

2.2.3. Clinical and laboratory markers of severity

Among objective clinical features, bloody stool and frequency, body temperature, and heart rate are good predictors of outcome. Laboratory markers have been studied extensively with varying degrees of success. The widely used acute phase C-reactive protein [CRP] is not as useful in UC as it is in Crohn's disease for the assessment of disease activity, except in acute severe colitis where standard values have been established both for adults and children.⁶¹⁻⁶³ In patients receiving parenteral steroids, a raised CRP > 45 mg/l 48 to 72 h following hospital admission for severe colitis together with three to eight stools a day is highly predictive for colectomy.⁶⁴ Elevated erythrocyte sedimentation rate [ESR], elevated serum procalcitonin,⁶⁵ and [low] albumin levels have been studied, but none has been demonstrated to be superior to CRP.⁶⁶ The most studied stool markers are faecal calprotectin and lactoferrin, though other markers such as elastase and S100A12 have also shown accuracy at detecting colonic inflammation.⁶⁷⁻⁷¹ Calprotectin has value for diagnosis and assessment of disease severity [having a good correlation with endoscopic indices, relapse, and response to treatment].⁷²⁻⁷⁶ Calprotectin can be used as a marker for relapse in patients with inactive inflammatory bowel disease [IBD]. Doubling of calprotectin levels was associated with an increased risk of relapse (hazard ratio [HR]: 2.01; 95% confidence interval [CI]: 1.52–2.65). It must be stressed, however, that none of these markers is specific for UC, since they mostly represent active colonic inflammation.

2.2.4. Remission

As with disease activity, there is no fully validated definition of remission. The consensus group agreed that the best way to define remission is a combination of clinical parameters [stool frequency \leq 3/day with no bleeding] and no mucosal lesions at endoscopy.⁷⁷

2.3. Classification according to age at onset or concomitant primary sclerosing cholangitis

ECCO statement 2C

A classification of ulcerative colitis according to age at onset is of value [EL2], as early-onset disease has a less favourable course. Classification according to the concomitant presence of primary sclerosing cholangitis is important as it increases the need for and frequency of surveillance colonoscopy [EL2]

Young patients (below 40 years [y]) with UC tend to have more aggressive disease and require more immunomodulators [IMs] and surgical intervention compared with later-onset disease.²⁹ All current available therapies for UC have shown an equivalent efficacy in children when compared with adults. The apparently higher risk of CRC in patients with childhood-onset UC almost certainly reflects the duration of disease. However, concomitant primary sclerosing cholangitis [PSC] is an important feature in patients with UC, as it increases the associated risk for CRC.^{7,43}

2.4. Use of molecular markers

ECCO statement 2D

The routine clinical use of genetic or serological molecular markers is not recommended for the classification of ulcerative colitis [EL2]

Detailed information on molecular markers can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{78–101}

Section 3. Diagnosis and Imaging

3.1. Clinical features and risk factors

3.1.1. Clinical features of ulcerative colitis

ECCO statement 3A

Symptoms of ulcerative colitis are dependent upon extent and severity of disease and include bloody diarrhoea, rectal bleeding, tenesmus, urgency, and faecal incontinence. Nocturnal defaecation and fatigue are often reported. Increasing bowel frequency, abdominal pain, anorexia, and fever suggest severe colitis [EL5]

UC primarily presents in late adolescence and early adulthood, although the diagnosis may be made at any age. A small peak in incidence has been demonstrated in some populations after the fifth decade of life.¹⁰² UC appears to affect both sexes equally. The inflammation characteristically commences in the rectum and extends proximally in a continuous, confluent, and concentric manner to affect a variable extent of the colon, or its entire mucosal surface. The proximal extent of inflammation may progress or regress over time, but after disease regression the distribution of inflammation tends to match the extent of previous episodes in the event of relapse. The view that UC represents continuous colonic inflammation has, however, been challenged by reports of a rectal sparing variant [more common in PSC] and peri-appendiceal patchy inflammation.¹⁰³

More than 90% of patients with active UC report having rectal bleeding. Associated symptoms generally reflect the severity of mucosal disease, and may differ according to disease extent.^{104–114} Loose stools [a decrease in stool consistency] for more than 6 weeks differentiates extensive UC from most cases of infectious diarrhoea.¹¹⁵ Patients with active disease also complain of rectal urgency, tenesmus, mucopurulent exudate, nocturnal defaecation, and crampy abdominal pain. In contrast, patients with proctitis usually present with rectal bleeding, urgency, tenesmus, and occasionally severe constipation.^{107,109} Although simple fistulae may occasionally occur in UC, recurrent or complex perianal fistulae should always raise the suspicion of Crohn's colitis.¹¹⁶

The onset of UC is usually insidious; symptoms are often present for weeks or even months before medical advice is sought. Presentation with a severe attack occurs in about 15%, with systemic symptoms including weight loss, fever, tachycardia, nausea, and vomiting.^{27,117,118} EIMs, in particular axial or peripheral arthropathy, episcleritis, and erythema nodosum may accompany the presentation in about 10–20% of cases and can precede intestinal symptoms in 10% of patients.^{7,119–132}

3.1.2. Risk factors for ulcerative colitis

ECCO statement 3B

A family history of ulcerative colitis or Crohn's disease increases the risk for developing ulcerative colitis [EL2]. Appendectomy for proven appendicitis before adulthood, and smoking, reduce the risk and severity of UC [EL3]. Smoking cessation may predispose to ulcerative colitis [EL3]

Relatives of patients with UC have an increased risk of developing the disease.¹³³ The risk of UC is greatest in first-degree relatives (incidence rate ratio [IRR]: 4.08; 95% CI: 3.81–4.38), but is also raised in second-degree [IRR: 1.85; 95% CI: 1.60–2.13], and third-degree relatives [IRR: 1.51; 95% CI: 1.07–2.12] of UC patients, as well as in relatives of patients with Crohn's disease although in a less pronounced fashion.¹³⁴

Tobacco intake protects against and reduces the severity of UC,^{56,135–137} but may not improve the natural history of the disease.¹³⁸ In contrast, ex-smokers have approximately a 70% higher risk of developing the disease, which is often more extensive and refractory to treatment compared with individuals who have never smoked.^{139–141} Smoking might protect against PSC or pouchitis, but the data are inconsistent.^{142–144}

Appendicitis and mesenteric lymphadenitis during childhood or adolescence are linked to a reduced risk of UC in adulthood.^{102,145–150} The protective effect of appendectomy is additional to that of smoking, but does not appear to protect against the development of PSC.¹⁵¹ When appendectomy is performed after the onset of UC, the effect [if any] on the course of disease is less clear and is subject to ongoing research.¹⁵²

Non-selective non-steroidal anti-inflammatory drugs [NSAIDs] may exacerbate the disease.^{56,139–141,153–157} In contrast, preliminary evidence from open-label studies and a double-blind controlled trial suggests that short-term treatment with selective COX-2 inhibitors is safe.^{156,158}

3.2. History, examination, and diagnosis

3.2.1. Medical history

ECCO statement 3C

A full medical history should include detailed questioning about the onset of symptoms, rectal bleeding, stool consistency and frequency, urgency, tenesmus, abdominal pain, incontinence, nocturnal diarrhoea, and extra-intestinal manifestations. Recent travel, possible contact with enteric infectious illnesses, medication [including antibiotics and non-steroidal anti-inflammatory drugs], smoking habit, sexual behaviour, family history of inflammatory bowel disease or colorectal cancer, and previous appendectomy should be recorded [EL5]

The diagnosis of UC is suspected in the context of compatible clinical symptoms. Infectious or drug-induced forms of colitis should be excluded. Family history and EIMs should be discussed.^{7,159-164}

3.2.2. Examination

ECCO statement 3D

Physical examination should include pulse, blood pressure, temperature, weight and height, and abdominal examination for distension and tenderness. Perianal inspection and digital rectal examination may be performed if appropriate. Physical examination may be unremarkable in patients with mild or moderate disease [EL5]

Findings on physical examination depend on the extent and severity of disease. Examination of patients with mild or moderate activity is usually unremarkable, apart from blood on rectal examination. Patients with a severe attack may exhibit fever, tachycardia, weight loss, abdominal tenderness, abdominal distension, and reduced bowel sounds.¹⁶⁵

3.2.3. Diagnosis

ECCO statement 3E

A 'gold standard' for diagnosis of ulcerative colitis does not exist. It is established by clinical, laboratory, imaging, and endoscopic parameters, including histopathology. An infective cause should be excluded. Repeat endoscopy with histopathological review after an interval may be necessary if diagnostic doubt remains [EL5]

The natural history of UC is characterised by episodes of relapse and periods of remission. An unremitting, continuous course occurs in approximately 5% of the cases, as does a single acute episode followed by prolonged remission.⁵⁵ The IBSEN study noted that approximately 60% of patients experienced a decrease in symptoms over time.⁵⁶ The frequency of relapse [pattern of disease] is usually defined during the first 3 years, and may be characterised as continuous [persistent UC symptoms without remission], frequent [≥ 2 relapses/year] or infrequent [≤ 1 relapse/year].³⁹ In the recent Epicom study, the proportion of patients with UC in remission rose from 11% at the time of diagnosis to 71% after 1 year of follow-up.²⁷ It is important to rapidly establish the diagnosis, extent, and severity of disease, as these influence treatment options and possibly disease progression.¹¹⁴ It is unreasonable to expect the histopathological analysis alone to lead to a diagnosis, but normal mucosal biopsies effectively exclude active UC as the cause of symptoms. In 10% of patients, the diagnosis may change to Crohn's disease or be refuted during the first 5 years.¹⁶⁶

3.3. Investigation and procedures to establish a diagnosis

3.3.1. Initial investigations

ECCO statement 3F

Initial investigations should include full blood count, electrolytes, liver and renal function, iron studies, vitamin D level, C-reactive protein, and faecal calprotectin [EL5]. The immunisation status should be assessed [EL5]. Infectious diarrhoea including *C. difficile* should be excluded [EL2]. Endoscopy and histology should be performed

At diagnosis, every patient should have a full blood count, inflammatory markers [CRP], electrolytes and liver function tests, and a stool sample for microbiological analysis.¹⁶⁵ Faecal calprotectin is an accurate marker of colonic inflammation. Laboratory markers of chronic inflammation may be normal in mild or moderate UC. The full blood count may reveal thrombocytosis as a result of the chronic inflammatory response, anaemia indicating severe or chronic active disease, and leucocytosis which raises the possibility of an infectious complication. For UC, and with the exception of proctitis, CRP broadly correlates with clinical severity.^{62,66,167-169} In patients with severe clinical activity, an elevated CRP is generally associated with an elevated ESR, anaemia and hypoalbuminaemia. These have been used as predictive biomarkers to assess the need for colectomy in acute severe colitis.^{63,64,170} CRP above 10 mg/l after a year of extensive colitis predicted an increased risk of surgery.^{122,171} Neither CRP nor ESR is specific enough to differentiate UC from infectious or other causes of colitis. Stool specimens should be obtained to exclude common pathogens and specifically assayed for *C. difficile* toxin. Additional tests may be tailored according to the medical history, for instance the examination of fresh, warm stool samples for amoebae or other parasites. Endoscopy [flexible sigmoidoscopy or colonoscopy] together with histological analysis are required at diagnosis and may be required to confirm disease relapse [see 3.2.3.].

3.3.2. Microbial investigations

ECCO statement 3G

Microbial testing is recommended in patients with colitis relapse. This includes testing for *C. difficile* and Cytomegalovirus infection [EL3]

Nosocomial *C. difficile* infection is a growing health problem and has been associated with higher mortality and health resources' utilisation.¹⁷²⁻¹⁷⁷ ECCO guidelines now recommend screening with every disease flare.¹¹ Moreover, microbial stool tests should be performed in the case of treatment-refractory or severe relapse.¹⁷⁸⁻¹⁸²

Reactivation of CMV can occur in UC, particularly [but not invariably] in immunosuppressed patients with severe colitis.¹⁸³⁻¹⁸⁵ Although CMV reactivation may not cause disease relapse, CMV infection can cause refractory or severe relapses. It should be excluded in patients who relapse while receiving immunosuppressant therapy. The optimal method for detecting clinically relevant CMV infection in patients with colitis has not been established, but most experts agree it requires histology/immunohistochemistry rather than polymerase chain reaction [PCR] detection of CMV in the blood. Occasional intranuclear inclusion bodies consistent with CMV on histopathology do not necessarily indicate clinically significant infection, but multiple intranuclear inclusions are usually significant.^{169,186-188} Further detail, including information on therapy, can be reviewed in the ECCO Consensus on OIs¹¹ and in a recent review.¹⁸⁹

3.3.3. Biomarkers

The most widely studied serological markers are perinuclear anti-neutrophil cytoplasmic antibodies [pANCA] and anti-*Saccharomyces cerevisiae* antibodies [ASCA]. Usually, pANCA are detected in up to 65% of patients with UC and in less than 10% of patients with Crohn's disease.^{190,191} Given the current limited sensitivity of these markers, their routine use for the diagnosis of UC and for therapeutic decisions is not clinically justified.

Several neutrophil-derived proteins such as calprotectin, elastase, lysozyme, and lactoferrin have been evaluated as markers of intestinal inflammation in IBD.^{192–195} Of these, faecal calprotectin appears to be the most sensitive.¹⁹⁶ Multiple studies emphasise the value of calprotectin in selecting patients for diagnostic investigation, in the assessment of disease severity [it correlates well with endoscopic indices], and in the diagnosis of relapse and response to treatment.^{72–75,197} As with all faecal tests, calprotectin lacks the specificity to discriminate between different types of inflammation; nevertheless, it represents a useful non-invasive marker in the follow-up of UC patients.^{198,199} Home-based calprotectin assessment provides a rapid method to measure gut inflammation and seems to be a reliable alternative to enzyme-linked immunosorbent assay [ELISA]; it presents a new way of monitoring patients by eHealth.²⁰⁰

3.4. Assessment of extent, severity, and activity

3.4.1. Discontinuous inflammation in UC

3.4.1.1. Rectal sparing and caecal patch

Macroscopic and microscopic rectal sparing has been described in untreated children with UC.^{201–203} In adults, a normal or patchy inflammation in the rectum is more likely to occur due to topical therapy.^{204,205} Patchy inflammation in the caecum is referred to as a ‘caecal patch’ and may be observed in patients with left-sided colitis. In the presence of macroscopic and histological rectal sparing or a caecal patch in newly diagnosed colitis, evaluation of the small bowel in addition to an ileo-colonoscopy is recommended. The natural history of patients with patchy right colonic inflammation seems to be similar to those with isolated left-sided UC.^{187,190}

3.4.1.2. Appendiceal skip lesions

Involvement of the appendix as a skip lesion is reported in up to 75% of patients with UC.²⁰⁶ Appendiceal inflammation has been associated with a more responsive course and a higher risk of pouchitis after ileal pouch anastomosis.^{207–210} Although both findings require confirmation, a recent retrospective study reported a similar clinical course in patients with an atypical distribution of inflammation when compared with those with a typical distribution in terms of remission, relapse, disease extension, colectomy, and mortality.²¹¹

3.4.1.3. Backwash ileitis

Continuous extension of macroscopic or histological inflammation from the caecum into terminal ileum is termed ‘backwash ileitis’, and is observed in up to 20% of patients with extensive colitis. Rarely, ileal erosions may occur in patients without caecal involvement, which challenges the pathogenic theory that maintains that backwash ileitis stems from a reflux of caecal contents into the ileum.^{212–214} Patients with backwash ileitis seem to be prone to a more refractory course of disease²¹³ which may include an increased risk of colon neoplasia in proctocolectomy specimens.²¹⁵ However, it does not appear to be correlated with poor pouch outcomes.²¹⁶ Additional imaging of the small bowel should be considered in cases of macroscopic backwash ileitis, to differentiate UC from Crohn’s disease.

3.4.1.4. Small bowel

Small bowel radiology, by follow-through, computer tomographic [CT] or magnetic resonance [MR] enterography, or capsule endoscopy, as reviewed in the ECCO consensus on diagnosis in Crohn’s disease²¹⁷ and small bowel endoscopy in IBD,¹⁰ is not routinely recommended. When differential diagnosis is difficult

[in the presence of rectal sparing, atypical symptoms, and/or macroscopic backwash ileitis], an extended diagnostic workup to exclude Crohn’s disease in addition to an ileo-colonoscopy is warranted.

3.4.2. Activity indices

ECCO statement 3H

Instruments for measuring clinical and/or endoscopic disease activity in ulcerative colitis are available. The incorporation of a simple clinical and/or endoscopic scoring system is desirable, to improve care of ulcerative colitis patients and to enhance a standardised IT system for inflammatory bowel disease [EL5]. Immediate admission to hospital is warranted for all patients fulfilling criteria for severe colitis, to prevent delayed decision making which may lead to increased perioperative morbidity and mortality [EL4]

The original classification of severe UC was proposed by Truelove and Witts in 1955.³² This classification is still considered to be the gold standard for rapid identification of outpatients in need of immediate admission to hospital and intensive treatment.^{218,219}

3.4.3. Investigations for acute severe colitis at admission

At the time of admission, patients with acute severe colitis should have full blood count, inflammatory markers [CRP or ESR], electrolytes, and liver function tests, along with a stool sample for culture and assay of *C. difficile* toxin.²¹⁹

A plain abdominal radiograph should be performed to exclude colonic dilatation [≥ 5.5 cm] and to estimate the extent of disease and look for features that predict response to treatment. The proximal extent of disease broadly correlates with the distal distribution of faecal residue; in a study reporting 51 episodes of severe colitis, the extent of disease was overestimated in 18% and underestimated in 8%.⁶⁴ The presence of mucosal islands [small, circular opacities representing residual mucosa isolated by surrounding ulceration] or more than two gas-filled loops of small bowel is associated with a poor response to treatment.^{220,221}

Flexible sigmoidoscopy should confirm the diagnosis of severe colitis and help exclude infection, particularly CMV.^{183,184,222} Empirical treatment may be required if CMV is strongly suspected [such as a patient on IMs with high fever], in which case urgent histopathology should be requested, potentially with a diagnosis within 4 h. Phosphate enema preparation before flexible sigmoidoscopy is considered safe.²²³ Full colonoscopy in patients with acute severe colitis is not recommended, in particular in patients on corticosteroids.²²⁴ Endoscopic criteria for severe colitis include haemorrhagic mucosa with deep ulceration, mucosal detachment on the edge of these ulcerations, and well-like ulceration,^{225,226} all of which can be assessed by flexible sigmoidoscopy.

3.4.4. Reassessment of extent and severity

ECCO statement 3I

Endoscopic remission is predictive of good outcome [EL2]. Endoscopic reassessment is appropriate at relapse, for steroid-dependent or -refractory ulcerative colitis or when considering colectomy [EL5]

Despite the importance of disease location in determining prognosis, risk of cancer, and choice of therapy, the appropriateness of periodic restaging after index colonoscopy has never been studied. In a Norwegian population-based cohort study, mucosal healing after 1 year of treatment was associated with a low risk of future colectomy, necessary in 1.6% of the patients with mucosal healing compared with 7% of those without healing.²²⁷ Another study showed 40% of patients who achieved endoscopic remission—defined as a lack of significant inflammation at endoscopy and on rectal biopsy—remained asymptomatic during 1 year of follow-up, in contrast to only 18% of patients that failed to achieve endoscopic remission.²²⁸ A hospital-based inception cohort analysis in patients with newly diagnosed UC, who were prescribed corticosteroid therapy, evaluated the disease course using clinical [Powel–Tuck] and endoscopic [Baron] indices after 3 and 6 months and then every 6 months. Outcomes at the third month [early response] were used to identify patients with complete, partial, or no response. After 5 years, significant differences between complete and partial responders in the rates of hospitalisation, immunosuppressive therapy, and colectomy were noted. Absence of mucosal healing was the only factor associated with negative outcomes and a more aggressive disease course.²²⁹ A prospective multicentre study analysed patients with active, mild-to-moderate UC treated with oral and rectal mesalamine. Those in clinical remission that presented with less severe endoscopic scores—defined as normal-looking mucosa with only mild redness and/or friability—were less likely to relapse after 1 year than patients solely in clinical remission.²³⁰

3.5. Endoscopy, ultrasound, and colonography

3.5.1. Endoscopic features

ECCO statement 3J

The most common endoscopic feature of ulcerative colitis is continuous, confluent colonic involvement with clear demarcation of inflammation and rectal involvement [EL2]. Endoscopically severe ulcerative colitis is defined by mucosal friability, spontaneous bleeding and ulcerations [EL2]

Endoscopic changes characteristically commence at the anal verge and extend proximally in a continuous, confluent, and concentric fashion. The demarcation between inflamed and normal areas is usually clear and may occur abruptly within millimetres, especially in distal disease.

A wide variation in the endoscopic interpretation of disease activity is acknowledged.²³¹ Granularity, vascular pattern, ulceration, and bleeding and/or friability have been reported to predict the global assessment of endoscopic severity²³²; bleeding and friability

are determinants within the Mayo score for UC, which is widely used for clinical trial recruitment [see Table 2.1.]. The Ulcerative Colitis Endoscopic Index of Severity [UCEIS] evaluates the vascular pattern and the presence of bleeding and ulceration, each with 3 or 4 levels of severity.²³¹ This is the first validated endoscopic index of severity in UC. The final UCEIS score is the sum of all three descriptors in the worst affected area of the colon visible at sigmoidoscopy. Although the original version of the UCEIS²³¹ attributed a score of 1 to the normal appearance of a descriptor, a decision was made to change the numbering of the levels: a normal appearance now corresponds to a score of 0, so that the simple sum of the UCEIS ranges from 0 to 8.²³³

The endoscopic features of mild inflammation are erythema, vascular congestion, and at least partial loss of the visible vascular pattern. Moderately active colitis is characterised by a complete loss of vascular pattern, blood adherent to the surface of the mucosa, and erosions, often with a coarse granular appearance and mucosal friability [bleeding to light touch]. Severe colitis is characterised by spontaneous bleeding and ulceration^{103,231,233–235} [see Table 3.1., in Dignass et al.¹]. In contrast to Crohn's disease, ulcers in severe UC are always embedded in inflamed mucosa. The presence of deep ulceration is a poor prognostic sign.²³⁴ In long-standing disease, mucosal atrophy can result in loss of haustral folds, luminal narrowing, and post-inflammatory ['pseudo'] polyps.²³⁶ The meaning of 'mucosal healing' in UC has therefore been the subject of detailed review.²³⁷

3.5.2. Colon capsule endoscopy

Detailed²³⁸ information on colon capsule endoscopy can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.

3.5.3. Abdominal ultrasound

Detailed information on abdominal ultrasound can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{239–244}

3.6. Colonic stenosis in ulcerative colitis

ECCO statement 3K

If colonic stenosis occurs in ulcerative colitis, multiple endoscopic biopsies should be taken to exclude carcinoma, followed by multidisciplinary team review. Computer tomographic colonography should be performed if biopsies are not obtained or the stricture is not traversed [EL5]

In long-standing UC, a colonic stricture signals an increased risk for CRC and requires careful histological assessment.²⁴⁵ Initially the

Table 2.1. Mayo score for ulcerative colitis^{33,239} [www.gastrojournal.org for full details].

Mayo index	0	1	2	3
Stool frequency	Normal	1–2/day > normal	3–4/day > normal	5/day > normal
Rectal bleeding	None	Streaks	Obvious	Mostly blood
Mucosa	Normal	Mild friability	Moderate friability	Spontaneous bleeding
Physician's global assessment	Normal	Mild	Moderate	Severe

dysplasia should be confirmed by a second pathologist [this is the most important aspect in the diagnosis of dysplasia] and then management discussed in a multidisciplinary team. If colonoscopy is incomplete due to a stricture, CT colonography should assess the mucosal pattern proximal to the stricture and exclude extra-intestinal pathology.²⁴⁶

Section 4. Histopathology

4.1. General

Histopathology is used for diagnosis, assessment of disease activity, and identification of intraepithelial neoplasia [dysplasia] and cancer. The following section represents extracts and updates of the ECCO guideline on histopathology.¹⁴

4.2. Microscopic features

UC is a chronic inflammatory process, limited to the mucosa. A large number of microscopic features have been evaluated, and they can be broadly classified into four main categories^{14,169,247}: mucosal architecture, lamina propria cellularity, neutrophil granulocyte infiltration, and epithelial abnormality.

Additional detailed information on microscopic features, specifically on the four main categories, can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{14,169,247–254}

ECCO statement 4A

For a reliable diagnosis of ulcerative colitis, a minimum of two biopsies from at least five sites around the colon [including the rectum] and the ileum should be obtained [EL 2]

ECCO statement 4B

Biopsies should be accompanied by clinical information, including endoscopic findings, duration of disease and current treatment. Samples should be fixed immediately by immersion in buffered formalin or an equivalent solution before transport [EL 5]

4.3. Microscopic features—appraisal of the diagnosis

4.3.1. Early stage disease

Not all the microscopic features found in UC are observed in early stage disease; only about 20% of patients show crypt distortion within 2 weeks of the first symptoms of colitis. The distinction from infectious colitis [acute self-limiting colitis], which is characterised by preserved crypt architecture and acute inflammation, is therefore a major concern.^{14,169}

ECCO statement 4C

Basal plasmacytosis is the earliest diagnostic feature with the highest predictive value for the diagnosis of ulcerative colitis [EL 3]. Preserved crypt architecture and the absence of a transmucosal inflammatory cell infiltrate do not rule out ulcerative colitis at an early stage. Repeat biopsies after an interval may help to solve differential diagnostic problems and establish a definitive diagnosis by showing additional features [EL 5]

Focal or diffuse basal plasmacytosis has been recognised as the earliest feature with the highest predictive value for UC diagnosis. It can be identified in 38% of patients within 2 weeks after symptoms presentation. During this period, the distribution pattern of basal plasmacytosis is focal, but may eventually change into a diffuse pattern throughout the disease course.²⁵⁰ Widespread mucosal or crypt architectural distortion, mucosal atrophy, and an irregular or villous mucosal surface appear later during the evolution of disease [at least 4 weeks after presentation].

4.3.2. Established disease

ECCO statement 4D

The microscopic diagnosis of ulcerative colitis is based upon the combination of widespread crypt architectural distortion and mucosal atrophy, and a diffuse transmucosal inflammatory infiltrate with basal plasmacytosis, with active inflammation causing cryptitis and crypt abscesses [EL 2]

The exact number of features needed for UC diagnosis has not been established. A correct diagnosis of UC is reached in approximately 75% of cases where two or three out of the four following features occur: severe crypt architectural distortion; severe decreased crypt density; an irregular surface; and heavy diffuse transmucosal inflammation, in the absence of genuine granulomas.^{251,255}

ECCO statement 4E

A decreasing gradient of inflammation from distal to proximal favours a diagnosis of ulcerative colitis [EL5]. Treatment may change the classical distribution pattern of inflammation. Awareness of these treatment-related effects is important in the evaluation of biopsies from treated patients to avoid misdiagnosis [EL3]

In an untreated patient, UC presents a typical pattern of continuous inflammation that begins in the rectum and extends proximally with a gradual decrease in severity. The transition between the involved and the normal mucosa is abrupt.^{14,169} However, unusual distribution patterns can occur.

In long-standing disease, the extent of gut involvement decreases during the natural evolution of the disease or after efficient therapy. Histology may show atypical features, such as change from continuous to discontinuous inflammation [‘patchiness’] and/or restoration of the rectal mucosa [rectal sparing].^{204,248,256} Awareness of these morphological features is important to avoid misdiagnosis, in particular the erroneous change of diagnosis to Crohn’s disease.^{14,168}

ECCO statement 4F

In quiescent disease, the mucosa may still show features related to architectural damage and recovery, as well as disappearance of basal plasmacytosis and increased transmucosal cellularity. Active inflammation is usually not observed [EL 3]

Quiescent [or clinically inactive] disease is characterised by the lack of active inflammation, i.e. mucosal neutrophils, whereas features related to chronic mucosal injury, such as crypt distortion and atrophy as well as Paneth cell metaplasia, may persist.^{14,169,257} Histological mucosal healing is characterised by the resolution of

crypt architectural distortion and inflammatory infiltrate.¹⁴ However, the mucosa can still show some features of sustained damage, such as decreased crypt density with branching and atrophy [shortening] of crypts. Reduced epithelial regeneration will usually reduce mucin depletion, i.e. restore the mucin content of epithelial cells.^{14,168}

4.4. Microscopic features—disease activity

ECCO statement 4G

Histological healing is distinct from endoscopic mucosal healing. Histological inflammation may persist in cases with endoscopically quiescent disease and has been associated with adverse outcomes [EL2]

Disappearance of mucosal inflammation following treatment has been observed²⁰⁵; thus biopsies can be used to distinguish between quiescent and active disease, as well as to assess the different grades of disease activity.¹⁴ Different scoring systems have been introduced for this purpose, particularly in therapeutic trials.^{60,257–261} No standard definition of histological remission or ‘histological mucosal healing’ exists.²⁵⁷ As a consequence, definitions of pathological remission range from residual inflammation with persistent architectural distortion, to normalisation of the colonic mucosa.²⁵⁷

Several histological features—such as epithelial damage in association with neutrophils, persistence of an increased transmucosal lamina propria cellularity with basal plasmacytosis and/or presence of basal lymphoid aggregates or a high number of eosinophils—have been associated with a substantial risk of relapse.^{14,262–267} The potential value of histopathology to predict relapses and to adequately evaluate the level of inflammation may have implications in therapeutic management.^{51,268}

Histological mucosal healing is distinct from endoscopic mucosal healing. Several studies have reported a higher sensitivity for histological diagnosis, with the microscopic analysis yielding more severe diagnoses than those suspected at endoscopy.^{266,269–271} Histological and endoscopic activity scores closely correlate in severe and inactive disease, but important misclassifications exist for mild disease.²⁷⁰ The value of histopathology as the [primary or secondary] endpoint to assess disease activity is frequently overlooked in clinical trials.^{257,272,273}

4.5. Microscopic features—upper gastrointestinal tract

Minimal to mild non-specific and focally enhanced gastritis may be present in children and adolescents diagnosed with UC.^{255,274–279}

Section 5. Extra-intestinal Manifestations

There follows extracts and updates of the ECCO guideline on EIMs⁷ and anaemia.¹⁵

5.1. Anaemia

Anaemia is common in UC, found in 21% of all patients.²⁸⁰

Table 5.1. Simple scheme for estimation of total iron requirement [from Dignass et al.¹⁵].

Haemoglobin g/dl	Body weight < 70 kg	Body weight ≥70 kg
10–12 [women]	1000 mg	1500 mg
10–13 [men]		
7–10	1500 mg	2000 mg

5.1.1. Diagnosis of anaemia

ECCO statement 5A [statement 1D in Dignass et al.¹⁵]

Diagnostic criteria for iron deficiency depend on the level of inflammation. In patients without clinical, endoscopic, or biochemical evidence of active disease, serum ferritin < 30 µg/l is an appropriate criterion [EL 2]. In the presence of inflammation, a serum ferritin up to 100 µg/l may still be consistent with iron deficiency [EL 4]

ECCO statement 5B [statement 1E in Dignass et al.¹⁵]

In the presence of biochemical or clinical evidence of inflammation, the diagnostic criteria for anaemia of chronic disease are serum ferritin > 100 µg/l and transferrin saturation < 20%. If the serum ferritin level is between 30 and 100 µg/l, a combination of true iron deficiency and anaemia of chronic disease is likely [EL2]

The most common forms of anaemia in UC are iron deficiency anaemia [IDA], anaemia of chronic disease, and a combination of both.^{281,282} Vitamin B₁₂ or folate deficiency, haemolytic anaemia, and drug-induced anaemia are less prevalent forms, but should also be considered.²⁸³ Anaemia is defined by the World Health Organization as a decline in blood haemoglobin to a concentration of < 12 g/dl [120 g/l] in women and < 13 g/dl [130 g/l] in men.^{15,284} All UC patients should be screened for anaemia, and this screening should include a full blood count, serum ferritin, and CRP levels.¹⁵

Anaemia should be investigated with red cell distribution width [RDW], mean corpuscular volume [MCV], reticulocyte count, full blood count [FBC], ferritin, transferrin saturation and CRP levels. Transferrin saturation is low with both IDA and inflammation. The plasma level of transferrin receptor increases with iron deficiency and is unaffected by inflammation.²⁸⁵ If the cause of anaemia remains unclear, further laboratory tests should include B₁₂, red cell folic acid, haptoglobin, and lactate dehydrogenase [see statement 1C in Dignass et al.¹⁵].^{286,287}

5.1.2. Treatment of ulcerative colitis-associated

ECCO statement 5C [statement 2A in Dignass et al.¹⁵]

Iron supplementation is recommended in all ulcerative colitis patients when iron deficiency anaemia is present [EL1]

anaemia

Detailed information on iron supplementation, B₁₂, folate, and blood transfusions can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{15,280,281,288–296}

5.2. Arthropathy

Joint involvement is the second most common EIM in UC, occurring in approximately 20% of all patients.²⁹⁷ Arthritis can be classified as axial and peripheral.²⁹⁸

ECCO statement 5D [statement 2D in Harbord et al.⁷]

Diagnosis of peripheral arthropathy and/or enthesitis associated with ulcerative colitis is based on signs of inflammation and exclusion of other specific forms of arthritis [EL3]

5.2.1. Peripheral arthropathy

A classification for peripheral arthropathy has been proposed, but not validated.²⁹⁸ Type I peripheral arthropathy is pauci-articular and typically affects less than five large joints in an asymmetrical pattern. This arthritis is acute and self-limiting, and is associated with intestinal disease activity. Type II peripheral arthropathy is a symmetrical and polyarticular arthritis, which typically affects more than five small joints, is independent of UC activity, and can persist for months to years.

ECCO statement 5E [statement 2B in Harbord et al.⁷]

Diagnosis of axial spondyloarthritis is on the basis of clinical features of inflammatory low back pain associated with magnetic resonance imaging or radiographic features of sacroiliitis [EL2]

5.2.2. Axial arthropathy

Axial arthropathy includes sacroiliitis and spondylitis.^{299–301} The diagnosis of ankylosing spondylitis [AS] is made according to the modified Rome criteria.³⁰² MR imaging [MRI] is the current gold standard, as it can show inflammation before bone lesions occur and become visible using plain radiology.^{303,304}

5.2.3. Treatment of arthropathy related to ulcerative colitis

The target of UC-associated arthritis management is the reduction of inflammation, alleviation of pain, and prevention of disability. So far, no single prospective controlled trial in IBD patients is available.^{305–308} In type I arthritis, successful treatment of the underlying UC flare usually resolves symptoms within weeks. Patients may further benefit from sulphasalazine, rest, and physiotherapy. Patients with type II arthritis usually require NSAIDs or systemic corticosteroids for symptom control. Treatment decisions for axial arthropathy should be shared with a rheumatologist. Sulphasalazine, methotrexate, and azathioprine are considered to be ineffective in AS with axial symptoms.³⁰⁹ In patients with active AS refractory to or intolerant of NSAIDs, anti-tumour necrosis factor [TNF] agents are recommended. The efficacy and safety of infliximab [IFX], adalimumab, and golimumab in AS are now well established.^{156,303,310–318} The American College of Rheumatology/Spondylitis Association do not recommend any particular NSAID as the preferred choice to decrease the risk of worsening the underlying IBD. They do recommend treatment with anti-TNF monoclonal antibodies, although not etanercept.³¹⁹

5.3. Metabolic bone disease

Diagnosing osteoporosis is based on bone densitometry [T-score < -2.5], which should be assayed in all patients with persistently active UC, especially if repeatedly exposed to corticosteroids or with long disease duration. Calcium [500–1000 mg/day] and vitamin D [800–1000 IU/day] are recommended should the T score drop below -1.5 [see statements 3A to 3C in Harbord et al.⁷]. Patients on systemic corticosteroid therapy should receive prophylactic calcium and vitamin D. Post-menopausal women or those with a history of spontaneous fractures should be prescribed regular bisphosphonates or other therapies, as these can prevent further bone loss [see statements 3B & 3D in Harbord et al.⁷].

5.4. Cutaneous manifestations

5.4.1. Erythema nodosum

ECCO statement 5F [statement 6A in Harbord et al.⁷]

Diagnosis of erythema nodosum is made on clinical grounds. In atypical cases, a skin biopsy might be helpful

[EL3]. Treatment is usually based on that of the underlying ulcerative colitis. Systemic steroids are required in severe cases [EL4]. Relapsing and resistant forms can be treated with immunomodulators or anti-TNF [EL4]

Erythema nodosum usually affects the extensor surfaces of the lower extremities, particularly the anterior tibial areas, and has a symmetrical distribution.³²⁰ It is closely related to disease activity, and its treatment is based on that of the underlying UC. Systemic corticosteroids are usually required. In resistant or recurrent cases, immunomodulation or anti-TNF may be used.^{321,322}

5.4.2. Pyoderma gangrenosum

ECCO statement 5G [statement 6B in Harbord et al.⁷]

Pyoderma gangrenosum can be treated with systemic corticosteroids [EL4], infliximab [EL1] or adalimumab [EL3], and topical or oral calcineurin inhibitors [EL4]

Pyoderma gangrenosum lesions are often preceded by trauma, a phenomenon known as pathergy.³²³ They most frequently occur on the shins and adjacent to postsurgical stomas. The correlation of pyoderma gangrenosum with disease activity is controversial.³²⁴ Corticosteroids [topical and/or systemic] are considered to be the first line of treatment. IFX has been effective^{325–327} and adalimumab has led to successful outcomes in reported cases, therefore anti-TNF treatment should be considered if a rapid response to corticosteroids is not achieved. Topical or oral calcineurin inhibitors are an alternative, but dermatological advice is recommended prior to its prescription.^{328,329}

Information on Sweet's syndrome and anti-TNF-induced skin inflammation can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{7,320,330–341}

5.5. Ocular manifestations

Episcleritis generally parallels UC activity. It can be self-limiting and usually responds to topical corticosteroids and NSAIDs prescribed alongside treatment of the underlying UC.³⁴² Simple episcleritis does not require referral to an ophthalmologist and may self-resolve. Uveitis has potentially more severe consequences. When related to UC, uveitis is frequently bilateral, has an insidious onset, and is long lasting.³⁴² The possibility of progression to loss of vision should prompt urgent referral to an ophthalmologist. Treatment usually consists of topical or systemic corticosteroid or NSAIDs.³⁴² Immunosuppressive and anti-TNF treatment have each been reported to be of value in resistant cases [see statements 4A & B in Harbord et al.⁷].

5.6. Hepatobiliary disease

PSC constitutes the most important hepatobiliary condition among UC patients.³⁴³ However, peri-cholangitis, steatosis, chronic hepatitis, cirrhosis, and gallstone formation are also over-represented in these patients. Many of the drugs used to treat UC have the potential to cause hepatotoxicity. PSC is a major risk factor for both cholangiocarcinoma and colon cancer.³⁴⁴ High-quality MR cholangiography [MRC] is recommended as a diagnostic test in patients with suspicion for PSC. If MRC is normal and small duct PSC is suspected, a liver biopsy should be considered [see statements 7A to 7C in Harbord et al.⁷].

Ursodeoxycholic acid was shown to improve the levels of liver enzymes and to reduce the risk of CRC in PSC, but no therapy has been shown to reduce time to liver transplantation, cholangiocarcinoma, or death.³⁴⁵⁻³⁴⁷ On the contrary, high-dose ursodiol treatment [> 20 mg/kg/day] was associated with a worse disease outcome and should therefore be avoided.³⁴⁸ Endoscopic retrograde cholangiopancreatogram [ERCP] remains the procedure of choice to manage significant biliary strictures.³⁴⁴ In advanced disease with liver failure, liver transplantation is the only known alternative [see statements 7D to 7F in Harbord et al.⁷].³⁴⁹ Annual or biennial [2-yearly] surveillance colonoscopy after diagnosis of PSC in UC patients is recommended [see statement 7G in Harbord et al.⁷ and 13E in Annese et al.¹³].

Information on pancreatitis, venous thromboembolism, and cardiopulmonary disease can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{7,126,350-361}

Section 6. Opportunistic Infections

6.1. Definitions and risk factors

ECCO statement 6A [statement 2B in Rahier et al.¹¹]

Ulcerative colitis patients at risk of opportunistic infections are those treated with immunomodulators [EL1], especially in combination [EL3], and those with malnutrition [EL5]. In addition, comorbidities and a history of serious infections should be considered. Age is an independent risk factor for opportunistic infections [EL3]

Conditions predisposing to OIs are classified according to the Center for Disease Control³⁶² as: [1] severe immune-depression; [2] human immunodeficiency virus [HIV]-infection related; and [3] limited immune deficits. An OI is defined as a progressive infection by a microorganism that has limited pathogenic capacity under normal conditions.³⁶³ Predisposing factors for OI can be either external [medical treatment, exposure] or inherent [age, comorbidity, malnutrition].¹¹ UC patients per se are not immunocompromised, but may have altered immune responsiveness as a consequence of their medical treatment [see statement 2A in Rahier et al.¹¹]. Older age is an independent risk factor for OI and OI-related adverse events in UC.^{364,365} Corticosteroids increase the risk of OI when administered in a dosage greater than 20 mg of prednisolone daily for more than 2 weeks.^{366,367} All IMs used for IBD increase the hazard of OI, and the use of more than one IM at a time may carry an increased risk of more than 14-fold.³⁶⁸ This risk is independent of the dose and type of IMs³⁶⁹ but may be influenced by patient age.^{366,370-372} Anti-TNF drugs alone double the likelihood of OI, especially tuberculosis [TB].³⁷³ However, anti-integrin antibodies have not been shown to increase the risk of OI.³⁷⁴

6.2. Viral agents

6.2.1. Hepatitis C virus [HCV], hepatitis B virus [HBV], and HIV

Given the increased risk of OI while receiving IMs, UC patients should be encouraged to receive HIV testing.¹¹ Seropositivity is not

ECCO statement 6B [statement 3B in Rahier et al.¹¹]

All ulcerative colitis patients should be tested for HBV [HBsAg, anti-HBcAb, anti-HBcAb] at diagnosis. In patients with positive HBsAg, viraemia [HBV-DNA] should also be quantified [EL2]

ECCO statement 6C [statement 3C in Rahier et al.¹¹]

HBV vaccination is recommended in all HBV anti-HBcAb seronegative patients with ulcerative colitis [EL5]. Efficacy of hepatitis B vaccination is impaired in inflammatory bowel disease, probably by the disease itself and by the anti-TNF drugs. Anti-HBs response should be measured after vaccination. Higher doses of the immunising antigen may be required to provide protection [EL 4]. Maintenance of HBs antibody should be monitored in patients at risk [EL 5]

ECCO statement 6D [statement 3D in Rahier et al.¹¹]

Before, during, and for at least 12 months after immunomodulator treatment has ceased, patients who are HBsAg positive should receive potent anti-viral agents [nucleoside/nucleotide analogues with high barrier to resistance] regardless of the degree of viraemia, in order to avoid hepatitis B flare [EL2]

ECCO statement 6E [adapted from statement 3E in Rahier et al.¹¹]

Reactivation of occult HBV rarely occurs with immunosuppressive therapy used in ulcerative colitis [EL2]. Viraemia [HBV DNA] should be assessed every 2–3 months but antiviral therapy is not recommended unless HBV-DNA is detected [EL5]

a definite contraindication for IMs [see statement 3F in Rahier et al.¹¹].³⁷⁵⁻³⁷⁷ UC patients should also be tested for HCV-Ab and, if positive, the result should be confirmed by HCV-RNA detection. IMs per se do not worsen HCV infection, unless a concomitant infection associated with HBV or HIV is present,³⁷⁸ but they can worsen the liver toxicity of medications in HCV-Ab positive subjects.

Information on CMV, HSV, VZV, EBV, HPV, or influenza virus can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.

6.3. Parasites and fungal agents

Additional information on parasites and fungal agents can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{11,185,357,379-400}

6.3.1. *Mycobacterium tuberculosis*

ECCO statement 6F [statement 6A in Rahier et al.¹¹]

Reactivation of latent tuberculosis in patients treated with anti-TNF is increased and is more severe than in the background population [EL2]. Latent tuberculosis should be diagnosed by a combination of patient history, chest X-ray, tuberculin skin test, and interferon-gamma release assays according to local prevalence and national recommendations. Screening should be considered at diagnosis and always performed before anti-TNF therapy [EL5]. Interferon-gamma release assays are likely to complement the tuberculin skin test and are preferred in BCG-immunised individuals [EL1]

Reactivation of latent TB is more likely to occur and be more severe in patients being treated with anti-TNF when compared with the background population.^{401–403} Patients with latent TB should receive anti-tuberculous therapy before starting anti-TNF. In patients with active UC and latent TB, anti-TNF should be administered only after 3 weeks of anti-TB chemotherapy [see statement 6B in Rahier et al.¹¹].^{404,405} In case of active TB, anti-tuberculous therapy must be started and anti-TNF withdrawn for at least 2 months [see statement 6C in Rahier et al.¹¹].^{404,405}

6.3.2. Bacterial agents

Pneumococcal vaccination should be offered to UC patients before starting IM, and should ideally be administered 2 weeks before treatment initiation. IM can impair immunity to *Streptococcus pneumoniae* after polysaccharide vaccination [see statement 7A & 7B in Rahier et al.¹¹].^{403,406} UC patients taking IM who develop pneumonia should be tested for pneumococcal infections and *Legionella pneumophila*.^{407,408} UC patients receiving IM therapy experience more severe infections with *Salmonella spp.* [see statement 7E in Rahier et al.¹¹]. Withholding IM until active infections are resolved is recommended [see statements 7C to 7E in Rahier et al.¹¹]. IMs, especially anti-TNF, increase the risk of systemic and central nervous infections with *Listeria monocytogenes* [see statement 7F in Rahier et al.¹¹].⁴⁰³ The same applies to *Nocardia spp.*-related systemic or skin infections [see statement 7G in Rahier et al.¹¹].^{373,409–411} Anti-TNF therapy should be withdrawn during infection, and infectious disease experts should be consulted before reintroducing IM.

ECCO statement 6G [adapted from statement 7H in Rahier et al.¹¹]

Ulcerative colitis is an independent risk factor for infection with *C. difficile* [EL3]

ECCO statement 6H [statement 7K in Rahier et al.¹¹]

Metronidazole and oral vancomycin are equally effective in treating mild to moderate *C. difficile*-associated disease [EL1]. It remains to be established if this applies to patients with ulcerative colitis. Other antibiotics should be stopped if possible. For severe disease, vancomycin has been shown to be superior in patients without ulcerative colitis [EL1] and is therefore preferable. In *C. difficile*-associated disease, use of immunomodulators should be guided by careful risk benefit evaluation and clinical judgement [EL4]

IMs are independent predictors of severe *C. difficile*-associated disease.^{11,413,413} Faecal microbiota transplantation is safe in UC.^{414,415} Fidaxomicin has been shown to be non-inferior in terms of clinical cure to vancomycin and showed a lower recurrence rate of *C. difficile*.⁴¹⁶ In addition to an increased risk for infection with *C. difficile*, patients with inflammatory bowel disease are 33% more likely to experience *C. difficile* recurrence.⁴¹⁷

Additional considerations can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{11,392,418,419}

Section 7. Fertility

ECCO statement 7A [adapted from statement 2A in van der Woude et al.¹⁶]

There is no evidence that ulcerative colitis affects fertility [EL3]. High levels of voluntary childlessness in women with ulcerative colitis indicate the need for better education [EL4]

UC patients are believed to have similar fertility as the general population,⁴²⁰ but female patients might benefit from better knowledge of pregnancy-related issues, as they often choose to remain childless.^{421–424} Female fertility does not seem to be affected by UC medications.⁴²⁴ Sulphasalazine, however, can reversibly decrease sperm count and motility [see statement 2B in van der Woude et al.¹⁶].^{425,426} whereas methotrexate [MTX] causes reversible oligospermia⁴²⁷ and is contraindicated in male patients aiming to father a child. Data about the effect of anti-TNF treatment are limited and conflicting.⁴²⁸ Ileo-anal pouch surgery in male patients may lead to erectile and ejaculatory dysfunction. However, by eliminating inflammation, surgery often leads to an overall unchanged or even improved sexual function [see statement 7A in van der Woude et al.¹⁶].^{429,430} The *in vitro* fertilisation success rate after pouch surgery is comparable to that of non-UC female subjects [see statement 2D in van der Woude et al.¹⁶].⁴³¹

ECCO statement 7B [statement 3A in van der Woude et al.¹⁶]

If conception occurs at a time of quiescent disease, the risk of relapse is the same as in non-pregnant women [EL3]. Conception occurring at a time of active disease increases the risk of persistent activity during pregnancy [EL3]. Pregnancy may influence the course of ulcerative colitis [EL3]

7.1. Pregnancy and delivery

7.1.1. Outcome of mothers

Patients should be advised to conceive during remission.^{16,432,433} In order to choose the most appropriate delivery method, a joint approach with gastroenterologist, surgeon, and obstetrician is recommended [see statement 3B in van der Woude et al.¹⁶].

7.1.2. Outcome of children

ECCO statement 7C [adapted from statement 4B, 4C and 4D in van der Woude et al.¹⁶]

Disease activity at conception or during pregnancy is associated with preterm birth and low birthweight [EL3]. The risk of congenital abnormalities in offspring from women with ulcerative colitis does not seem to be increased [EL2]. Fetal exposure to most ulcerative colitis medications is considered of low risk to the child, except for methotrexate and thalidomide [EL2]

Additional information on outcome of children can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{16,434–444}

7.2. Pregnancy and ulcerative colitis management

ECCO statement 7D [statement 5A in van der Woude et al.¹⁶]

Appropriate treatment of ulcerative colitis should be maintained in those patients who wish to conceive, in order to reduce the risk of flares during pregnancy [EL5]. Acute flares during pregnancy carry a high risk of adverse maternal and fetal outcome, and are best treated appropriately and without delay to prevent these complications [EL3]

UC patients who conceive should be advised to continue their medication to avoid disease flares and possible related pregnancy complications [see statement 5F in van der Woude *et al.*¹⁶].^{439,445} Due to their safety profile during pregnancy, 5-aminosalicylic acid [5-ASA] derivatives [preferably avoiding 5-ASA with dibutylphthalate coating^{446,447}] and corticosteroids should be considered as the first-line treatment should a relapse occur.^{448,449} Anti-TNF is an option in specific situations [see statement 5C in¹⁶]. Sulphasalazine administration should be implemented in a parallel with high-dose folic acid supplementation. Surgery for UC during pregnancy can lead to miscarriage during the first trimester and to preterm labour in the third trimester,⁴⁵⁰ but continued illness is considered to represent a greater risk for the fetus [see statement 5E in van der Woude *et al.*¹⁶].⁴⁵¹

Additional information on lactation, endoscopy, and imaging can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{16,452–462}

Section 8. Surveillance for Colorectal Cancer in Ulcerative Colitis

8.1. Risk of colorectal cancer in ulcerative colitis

Although it is generally accepted that long-standing UC is associated with an increased risk of CRC, the reported risk estimates vary widely between studies. In 2001, Eaden *et al.* described a meta-analysis including 116 studies⁴⁶³ and concluded that after 30 years of disease duration the cumulative risk was 18%. Another meta-analysis revealed that the pooled SIR [standardised incidence ratio] of CRC in UC patients was 2.4.⁴⁶⁴ However, the risk of CRC may have been declining over time.^{465,466} An Australian study has reported a CRC cumulative incidence of 1% at 10 years, 3% at 20 years, and 7% at 30 years.⁴⁶⁷ This may reflect the increased implementation of surveillance strategies, the introduction of drugs that control inflammation more effectively, or the changing approach to maintenance therapy or colectomy.¹³

ECCO statement 8A

The risk of colorectal cancer in ulcerative colitis is increased compared with the general population. Risk is associated with disease duration [EL 2], extent [EL 2], and more severe or persistent inflammatory activity [EL 2]

Although it has been stated that CRC is rarely encountered when disease duration falls below 8 years, a significant number of tumours may still develop by this time,^{468,469} especially in patients who are older at colitis onset or in patients with PSC. Patients with extensive colitis carry the highest risk of CRC, whereas left-sided colitis patients present an intermediate risk. CRC risk is not increased in patients with UC limited to the rectum.^{463,470} Of note, histological extent, even without endoscopically visible abnormalities, may be an important determinant for CRC risk.^{471,472}

ECCO statement 8B

Concomitant primary sclerosing cholangitis [EL 2] and a family history of colorectal cancer [EL 3] confer an additional risk for colorectal cancer

The most consistent risk factors reported for CRC are PSC [with an increased absolute risk of up to 31%]^{473–477} and histological disease activity.^{50,51} Post-inflammatory polyps may be markers of previous inflammatory severity, and have also been found to be a strong risk factor.^{247,480} Family history of CRC is associated with an increased risk, although the risk varies across studies.^{474,479} Jess *et al.*

found that men had a greater risk of developing CRC [SIR: 2.6; 95% CI: 2.2–3.0] than women [SIR: 1.9; 95% CI: 1.5–2.3].⁴⁶⁴ In multivariate logistic regression analysis, CRC was associated with male gender, disease duration, extensive colitis, concomitant PSC, median albumin levels, and an increased CRP-albumin score.⁴⁸⁰

8.2. Surveillance issues

8.2.1. Screening and surveillance

Given that an increased risk of CRC is associated with dysplastic change in colonic mucosa, surveillance colonoscopy programmes have been developed in order to reduce CRC-associated morbidity and mortality. These surveillance programmes involve not only a systematic colonoscopic assessment, but also a revision of the patients' symptoms, medications, and laboratory test results, as well as an update of personal and family medical histories. At the onset of these programmes, an initial screening colonoscopy is performed to reassess disease extent and confirm the absence of dysplastic lesions.

ECCO statement 8C

Surveillance colonoscopy may permit earlier detection of colorectal cancer with a corresponding improved prognosis [EL 3]

8.2.2. Effectiveness

The efficiency of surveillance colonoscopy programmes has yet to be assessed by randomised controlled trials. However, a large number of case series suggest a positive impact.^{13,472,481} Reduced CRC incidence reported in recent studies may be proof of their efficiency, although other potential factors [including better disease control] may also be relevant.¹¹⁴ A systematic review was unable to demonstrate a benefit of surveillance programmes in the prevention of CRC-related death in UC when limiting the analysis to studies that included a control group.¹¹⁴ Two large case series have shown improved survival in surveillance patients due to an early detection of CRC.^{466,482} Three retrospective case control studies have shown a correlation between surveillance colonoscopy and reduced odds ratio of CRC.^{478,483,484} Unequivocal evidence for the benefit of surveillance colonoscopy is still lacking.

8.2.3. Initial screening colonoscopy and surveillance schedules

ECCO statement 8D [adapted from statement 13D in Annese *et al.*¹³]

Screening colonoscopy should be offered over 8 years following the onset of symptoms to all patients to reassess disease extent and exclude dysplasia [EL 5]

ECCO statement 8E

When disease activity is limited to the rectum without evidence of previous or current endoscopic and/or microscopic inflammation proximal to the rectum, inclusion in a regular surveillance colonoscopy programme is not necessary [EL2]

ECCO statement 8F

In patients with concurrent primary sclerosing cholangitis, annual surveillance colonoscopy should be performed following the diagnosis of primary sclerosing cholangitis, irrespective of disease activity, extent, and duration [EL3]

ECCO statement 8G [adapted from statement 13E in Annese et al.¹³]

Ongoing surveillance should be performed in all patients apart from those with proctitis [EL3]. Patients with high-risk features [e.g. stricture or dysplasia detected within the past 5 years, primary sclerosing cholangitis, extensive colitis with severe active inflammation] should have their next surveillance colonoscopy scheduled for 1 year [EL4]. Patients with intermediate risk factors should have their next surveillance scheduled for 2 to 3 years. Intermediate risk factors include extensive colitis with mild or moderate active inflammation, post-inflammatory polyps, or a family history of colorectal cancer in a first-degree relative diagnosed at age 50 years and above [EL5]. Patients with neither intermediate nor high-risk features should have their next surveillance colonoscopy scheduled for 5 years [EL5]

Supporting information on risk factors for CRC with and without dysplasia on biopsies can be found in Supplementary materials, available as Supplementary data at *ECCO-JCC* online.^{3,13,49,50,473,485-495}

8.3. Colonoscopy

ECCO statement 8H

Colonoscopic surveillance is best performed when ulcerative colitis is in remission, because it is otherwise difficult to discriminate between dysplasia and inflammation on mucosal biopsies [EL5]

As happens with screening colonoscopies in the otherwise healthy population, the quality of the preparation in UC patients significantly affects the lesion detection rate.⁴⁹⁶ Good bowel preparation is essential for an efficient surveillance colonoscopy. Repetition of the colonoscopy should be considered when excess faecal residue is present.

ECCO statement 8I

Surveillance colonoscopy should take into account local expertise. Chromoendoscopy with targeted biopsies has been shown to increase dysplasia detection rate [EL2]. Alternatively, random biopsies [quadrantic biopsies every 10 cm] and targeted biopsies of any visible lesion should be performed if white light endoscopy is used [EL3]. High-definition endoscopy should be used if available

Endoscopic equipment, patient preparation, and diagnostic techniques have advanced considerably during recent years. High-resolution equipment improves imaging quality, and may therefore improve the dysplasia detection rate. In fact, a recent colitis surveillance study has shown that high-definition colonoscopy improves dysplasia detection in comparison with standard definition.⁴⁹⁷ Targeted biopsies have been shown to be non-inferior to random biopsies for neoplasia detection rate per colonoscopy in a randomised controlled trial [RCT].⁴⁹⁸

Dysplasia detection in surveillance colonoscopy can be improved by spraying dyes that highlight subtle changes in the colonic mucosa architecture.⁴⁹⁹ Using this technique, random biopsies of apparently normal mucosa are of negligible additional value although they do enable an assessment of microscopic disease extent and activity.

The chromo-endoscopic diagnostic yields are similar using methylene blue or indigo carmine.⁵⁰⁰⁻⁵⁰²

A meta-analysis including six studies [1277 patients] has shown that the difference in dysplasia detection between chromo-endoscopy and white light endoscopy [WLE] was 7% [95% CI: 3.2-11.3], on a per patient analysis (number needed to treat [NNT] 14.3). The absolute difference in lesions detected by targeted biopsies was 44% [95% CI: 28.6-59.1] and flat lesions was 27% [95% CI 11.2-41.9], both in favour of chromo-endoscopy.⁵⁰³ Another meta-analysis has focused on the diagnostic accuracy of chromo-endoscopy compared with that of histology, and has reported a sensitivity of 83.3% and a specificity of 91.3% for chromo-endoscopy in detection of intraepithelial neoplasia.⁵⁰⁴ Superiority of chromoendoscopy compared with white light endoscopy for dysplasia detection has also been shown in real-life studies outside clinical trials.⁵⁰⁵ This finding does not vary with operator familiarity or with the availability of high-resolution endoscopy. Currently narrow band imaging as well as endomicroscopy cannot currently be recommended for dysplasia screening in IBD. Additional information can be found in Supplementary materials, available as Supplementary data at *ECCO-JCC* online.⁵⁰⁶⁻⁵¹⁰

8.4. Chemoprevention

8.4.1. Mesalamine and colorectal cancer

Additional information can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{6,245,474,478,484,486,511-521}

8.4.2. Patient selection for chemoprevention with 5-ASA

ECCO statement 8J

Chemoprevention with mesalamine compounds may reduce the incidence of colorectal cancer in ulcerative colitis [EL2]. There is insufficient evidence to recommend for or against chemoprevention with thiopurines

In a nested case-control study of the CESAME cohort, adjusted for the propensity of receiving 5-ASA, a sub-analysis was performed in IBD patients with or without long-standing [> 10 years] and extensive [> 50% of colonic mucosa at any time] colitis.⁵²² The protective odds ratio was significant for patients with long-standing extensive colitis [OR: 0.5; 95% CI: 0.2-0.9] although it was not in the remaining patients [OR: 0.8; 95% CI: 0.3-1.7]. This suggests a chemopreventive effect of 5-ASA in patients with known risk factors for dysplasia or cancer. However, statements on the chemopreventive effect of 5-ASA in UC are not restricted to high-risk individuals,^{6,40,485} which justifies lifelong chemoprevention from diagnosis in all patients, except for those with isolated proctitis.^{6,40,49-51,245,471,472,485,512,523-526} Additional information can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{6,40,49-51,238,456,458,465,469,494,505-507}

8.4.3. Immunosuppressants

IMs [e.g. thiopurines and MTX] and biologics [anti-TNF] could theoretically either increase the risk of CRC via immunosuppression, or be chemopreventive via a reduction of chronic mucosal inflammation. There are no data for MTX or anti-TNF, and the data for thiopurines are conflicting.^{49-51,478,511,519,527-529} These included the published studies specifically designed to address the chemopreventive effect of thiopurines on the risk of CRC in IBD.^{528,529} Overall, a recent meta-analysis failed to show a significant chemopreventive effect of thiopurines [OR: 0.87; 95% CI: 0.71-1.06].⁵³⁰ This did not change significantly in subgroup analysis of the two population studies [OR:

0.87; 95% CI: 0.71–1.06], the 13 clinic-based studies [OR: 0.87; 95% CI: 0.59–1.09], the seven cohort studies [OR: 0.93; 95% CI: 0.67–1.28], or the eight case-control studies [OR: 0.83; 95% CI: 0.65–1.08]. A recent observational cohort study from the CESAME group, however, indicated that patients with long-standing extensive colitis on thiopurine therapy may have a lower overall risk for CRC compared with patients not on thiopurines [HR: 0.28; 95% CI: 0.1–0.9].⁴⁷⁰ There is currently insufficient evidence to recommend for or against chemoprevention with thiopurines; however, thiopurines may increase the risk for urinary tract cancers,⁵³¹ acute myeloid leukaemia [AML], myelodysplastic syndrome,⁵³² lymphoproliferative disorders,³⁹⁰ and non-melanoma skin cancer.⁵³³

8.4.4. Other drugs

Additional information on other drugs for chemoprevention can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{6,40,346,485,534}

8.5. Management of dysplasia

Therapeutic recommendations for management of dysplasia in UC are based on macroscopic pattern [polypoid, non-polypoid, or macroscopically invisible] and microscopic characteristics of the lesion [indefinite, low grade or high grade].^{535–537}

8.5.1. Microscopic patterns of dysplasia

The current, widely used definition of dysplasia was proposed by Riddell *et al.* in 1983.⁵³⁷ Dysplasia was defined as an unequivocal neoplasia of the epithelium confined to the basement membrane, without invasion into the lamina propria. Dysplasia is the best and most reliable marker of an increased risk of malignancy in patients with IBD.⁵³⁸ Dysplasia [intraepithelial neoplasia] is now generally classified according to the grade of neoplastic change into three morphological categories: ‘indefinite’, ‘low-grade’ [LGD], or ‘high-grade’ [HGD].⁵³⁷ However, dysplasia almost certainly evolves along a progressive [continuous] scale rather than in discrete categories. This contributes to the significant degree of variability in interpretation of the grade of dysplasia even among experienced gastrointestinal pathologists.^{539,540} Levels of agreement are highest for the category of HGD and for specimens considered negative for dysplasia, and lower for specimens in the indefinite and LGD categories. These limitations in the assessment of dysplasia have led to the recommendation that histological slides should be reviewed by a second expert gastrointestinal pathologist.

ECCO statement 8K

Presence of low-grade or high-grade dysplasia should be confirmed by an independent gastrointestinal specialist pathologist [EL 5]

8.5.2. Macroscopic patterns of dysplasia

There is inconsistency in the literature about the definitions used to designate the macroscopic characteristics of dysplastic lesions in UC.^{493,536} Terms such as dysplasia-associated lesion or mass [known as ‘DALM’], adenoma-like, non-adenoma like, and flat, often cause confusion among endoscopists as they are often used to describe a variety of differently shaped lesions. Thus, in agreement with the SCENIC international consensus, these terms should be abandoned.⁵⁴¹ Dysplasia detected during surveillance procedures should be classified into three categories: polypoid, non-polypoid, and

endoscopically invisible. A polypoid lesion refers to pedunculated [Paris type Ip—attached to the mucosa by a stalk] or sessile [Paris type Is—not attached to the mucosa by a stalk and the entire base is contiguous with the mucosa] lesions that protrude from the mucosa into the lumen ≥ 2.5 mm.⁵⁴¹ These lesions are usually endoscopically removable by routine endoscopic methods.^{40,485} ‘Non-polypoid’ lesion refers to Paris type IIa [superficially elevated < 2.5mm], IIb [flat—no protrusion], IIc [depressed], velvety patches, plaques, irregular bumps and nodules, wart-like thickenings, stricturing lesions, and broad-based masses,^{493,542–544} and may not be amenable to removal by colonoscopic polypectomy. Polypoid and non-polypoid dysplasia are differentiated on the basis of their gross [endoscopic] appearance. Histological features may be helpful,⁵⁴⁵ although both types of lesions may appear identical.^{546,547} Endoscopically invisible dysplasia refers to dysplasia found during histological examination in the absence of a visible lesion at colonoscopy.

8.5.3. Management of endoscopically visible dysplasia

ECCO statement 8L

Polypoid dysplasia can be adequately treated by polypectomy provided the lesion can be completely excised, and there is no evidence of non-polypoid or invisible dysplasia elsewhere in the colon [EL 2]

ECCO statement 8M

Non-polypoid dysplastic lesions can be treated endoscopically in selected cases. If complete resection can be achieved, with no evidence of non-polypoid or invisible dysplasia elsewhere in the colon, continued surveillance colonoscopy is reasonable [EL 5]. Every other patient with non-polypoid dysplasia should undergo colectomy, regardless of the grade of dysplasia detected on biopsy analysis [EL 2]

ECCO statement 8N

Polyps with dysplasia that arise proximal to segments with macroscopic or histological involvement are considered as sporadic adenomas and should be treated accordingly [EL 2]

Polypoid dysplasia arising in a colonic segment currently, or previously, affected by colitis can be adequately treated with polypectomy and continued surveillance. Four studies have shown no significant difference in the incidence of polyp detection on follow-up between patients with UC and polypoid dysplasia, and patients with UC and a sporadic adenoma, or between either of these two groups of UC patients and a non-UC sporadic adenoma control group.^{3,245,545,548,549} Recent literature continues to support this strategy. Data from a St Mark’s Hospital, UK, cohort of 172 patients with LGD showed that the cumulative incidence of developing HGD or CRC at 5 years after the initial detection of polypoid dysplasia was 6%.⁴⁷² A meta-analysis of 10 studies comprising 376 patients demonstrated that the pooled incidence of CRC after endoscopic resection of polypoid dysplasia was 5.3 cases per 1000 patient-years of follow-up [95% CI: 2.6–10.1 cases].⁵⁵⁰ Thus, provided that the polypoid lesion can be completely excised, shows absence of dysplasia at the margins of the specimen, and there is no evidence of

non-polypoid or invisible dysplasia elsewhere in the colon, colectomy is not necessary. It is important to obtain biopsies from the immediate surrounding flat mucosa to ensure that there is no adjacent dysplasia. Patients undergoing endoscopic resection for polypoid lesions have an approximately 10-fold risk of developing further dysplasia.⁵⁵⁰ Therefore, close monitoring preferably with chromo-endoscopy is recommended at 3–6 months before reverting to annual surveillance. Partial colonic resection, if dysplasia is visible and not endoscopically resectable, or future surveillance in the context of LGD might also be a potential option.

Non-polypoid dysplasia is a more ominous finding. The natural history of these lesions was recently studied in depth, where authors investigated 172 UC patients diagnosed with LGD in the St Mark's Hospital surveillance cohort.⁴⁷² The cumulative incidence of HGD or CRC development after 5 years was 6.0% for polypoid dysplasia and 65.2% for non-polypoid dysplasia. Furthermore, non-polypoid dysplasia was more likely to be multifocal compared with polypoid lesions and often progressed to synchronous CRC. These data support findings from earlier studies, where there was a strong association of metachronous or synchronous carcinoma with non-polypoid dysplasia, ranging from 38% to 83%.⁵³⁶ For this reason, it is generally recommended that patients with UC and endoscopically unresectable non-polypoid dysplasia should undergo immediate colectomy, regardless of the grade of dysplasia detected by biopsy analysis. Currently, there are no dedicated studies investigating long-term outcome of patients who undergo endoscopic resection for non-polypoid dysplasia. A subgroup analysis of the aforementioned St Mark's study revealed that one of eight patients [12.5%] who underwent endoscopic resection for small non-polypoid LGD [all < 1 cm] developed Dukes' A CRC with a median follow-up time of 44 months.⁴⁷² Although this should be interpreted with caution given the small number of cases, it implies that colectomy may not always be necessary for a subgroup of patients diagnosed with non-polypoid dysplasia. Furthermore, one study showed that patients are likely to refuse colectomy if they were told that they have dysplasia and have 20% chance of having CRC 'right now'.⁵⁵¹ Based on this, despite the lack of evidence, continued surveillance can be considered reasonable if the non-polypoid lesion can be resected in full and if there is no evidence of invisible or non-polypoid dysplasia elsewhere in the colon. In all cases, a full discussion should occur with the patient so that they are made aware of the potential risk and benefits of taking either approach [i.e. endoscopic resection versus colectomy]. Again, close monitoring, preferably with chromo-endoscopy, is recommended at 3 to 6 months before reverting to annual surveillance. Finally, if a dysplastic polyp occurs in an area proximal to the microscopic level of inflammation, with no dysplasia in flat mucosa, it can be regarded as a sporadic adenoma and treated accordingly.^{549,552}

8.5.4. Management of endoscopically invisible dysplasia

Macroscopically invisible dysplasia describes dysplasia within random biopsies in the absence of visible lesions during colonoscopy. It is difficult to estimate its true risk as many 'invisible' dysplastic lesions reported in previous studies were recorded in the pre-video endoscopic era. This makes it difficult to know whether these represent truly invisible dysplasia or merely subtle non-polypoid lesions that were previously undetected, but that could now be visualised with newer techniques. However, there is indirect evidence suggesting that invisible dysplasia is becoming rare. In the Bernstein *et al.* review of 10 prospective studies performed in the pre-video endoscopic era [published in 1994], the majority of dysplasia was

invisible [272/312 = 87%.]⁵¹⁵ This is in contrast with the recent data from the St Mark's cohort study of UC patients diagnosed with LGD, where only 16 out of 172 [9%] had invisible dysplasia.

These observations indicate that the majority of invisible dysplasia reported in older studies may have been subtle lesions undetected by older endoscopes. Based on this observation, when dysplasia is identified from random biopsies, the patient should be referred to an endoscopist with expertise in IBD surveillance to have a repeat examination preferably with chromo-endoscopy using a high-definition endoscope, to determine whether a well-circumscribed lesion exists and can be resected and to assess for synchronous dysplasia. Of note, the recent study from St Mark's reported that the detection rate for non-polypoid lesions was significantly higher with chromo-endoscopy compared with standard white-light colonoscopy. Although this should be interpreted with caution given that this was not a dedicated study, it nevertheless supports reassessing these patients with the more advanced techniques.

If a visible lesion is found in the same region of the colon as the invisible dysplasia, patients should be managed appropriately as described in section 8.5.3. If no visible lesion is identified, its management depends on the grade of initial dysplasia. It is generally accepted that the immediate and subsequent risk of CRC in patients with invisible HDG is high enough to warrant recommendation for colectomy [reviewed in 2012 ECCO guidelines³].

Recommendations on the optimal management of UC patients with endoscopically invisible LGD are more controversial, as the risk of progression to more advanced neoplasia varies greatly in the literature [reviewed in 2012 ECCO guidelines³]. This can be as low as 3% after 10 years⁴⁸⁹ to as high as 53% at 5 years⁵⁵³ since the date of initial detection. In the recent St Mark's series, the 5-year progression rate was 21.9%, which was higher than that of polypoid lesions [6.0%] but lower than that of non-polypoid lesions [65.2%].⁴⁷²

Thus, given that the relevance of the existing evidence is questionable and that reports are contradictory, the current evidence is insufficient to assess the balance of risk and benefit of colectomy for endoscopically invisible LGD. The decision to undergo colectomy versus continued surveillance in patients with flat LGD should be individualised and discussed at length between the patient, the gastroenterologist, and the colorectal surgeon. Colectomy will eradicate the risk of CRC, but if a patient is unwilling to undergo colectomy, annual surveillance is recommended.⁴⁸⁵ The 2013 ECCO endoscopy guideline recommended that a patient with confirmed LGD detected in mucosa without an associated endoscopically visible lesion should undergo repeat chromo-endoscopic colonoscopy with additional random biopsies within 3 months.¹³

Section 9. Surgery

9.1. General

This section summarises the ECCO consensus guidelines on surgery in UC patients.¹² It should be noticed that the level of evidence of these surgical guidelines is rather modest because robust evidence stemming from randomised studies is still lacking in the literature.

Surgery for UC has been refined to offer a better quality of life to patients who need to undergo a colectomy. Until the early 1980s, and apart from the sporadic use of ileo-rectal anastomosis, the gold standard for surgery was a procto-colectomy with an ileostomy. The Kock continent ileostomy was introduced in the late 1960s but has never achieved universal acceptance, in spite of the fact that the quality of life when compared with procto-colectomy with a conventional stoma seemed to be clearly higher.⁵⁵⁴ In the past 20 years,

the new gold standard is the restorative procto-colectomy with an ileal pouch-anal anastomosis [IPAA], offering patients an unchanged body image with no stoma and a preserved anal route of defaecation.⁵⁵⁵ Nevertheless, bowel function is not restored, and therefore both functional outcomes and quality of life after an IPAA should be compared with those after an ileostomy.⁵⁵⁶

9.2. Technical considerations

9.2.1. Surgery for acute severe colitis

ECCO statement 9A

Delay in surgery is associated with an increased risk of surgical complications [EL 4]. A staged procedure, initially with sub-total colectomy, is recommended in acute colitis [EL 4] in patients taking ≥ 20 mg prednisolone daily for more than 6 weeks, or in those treated with anti-TNF [EL 3]. If the appropriate skills are available, a laparoscopic approach is preferred [EL 3]

Joint care including senior surgeons and senior gastroenterologists remains essential for the safe management of acute severe colitis. Whereas medical therapy is effective in many cases, there is clear evidence that a delay in appropriate surgery is detrimental to patient outcomes.⁵⁵⁷ A staged procto-colectomy [with subtotal colectomy first] is considered to be a wise first step in the surgical treatment of acute severe colitis or if patients have received prolonged steroid therapy [over 20 mg of prednisolone/day for more than 6 weeks]. A subtotal colectomy with an ileostomy will spare patients from the burden of colitis. As a consequence, they will regain general health, normalise nutrition, and have the time to consider carefully the options of an IPAA or of a permanent ileostomy. A preliminary subtotal colectomy also allows the clarification of the pathology, definitively excluding Crohn's. Subtotal colectomy is a relatively safe procedure even in critically ill patients.⁵⁵⁸⁻⁵⁶⁰ In a recent systematic review of laparoscopic versus open colectomy for non-toxic colitis, laparoscopic surgery resulted in less wound infections and intra-abdominal abscesses and a shorter hospital stay.⁵⁶¹ Emerging evidence supports that the same holds true for emergency colectomy.^{562,563}

9.2.2. Managing the rectal remnant

Critical aspects need to be considered when performing a subtotal colectomy leaving a rectal remnant. Leaving as little rectum as possible [i.e. dividing the middle rectum within the pelvis] is not recommended, because such an approach will impose difficulties at subsequent proctectomy, with a probable increase in the risk of pelvic nerve injury. The alternatives are to divide the rectum at the level of the promontory [i.e. at the recto-sigmoid junction], or to leave the distal part of the sigmoid colon in situ. This allows the bowel to be anchored to the anterior abdominal wall, which facilitates its subsequent identification and dissection or its relocation through the abdominal fascia, either closed in the subcutaneous fat or brought forward as a mucous fistula. The latter option is considered to be safe, as no closed bowel is left within the abdomen. However, a mucous fistula results in an extra stoma for the patient, which may not be easily managed.⁵⁶⁴ Closing the stump and leaving it within the subcutaneous fat is also a safe approach, although the skin should be allowed to heal through secondary intention in order to avoid wound infection.⁵⁶⁵ There are no studies yet on the risk of subsequent inflammation or bleeding after leaving different

lengths of rectum or recto-sigmoid colon in situ. When the rectum is transected within the abdominal cavity at the promontory level, it is advisable to perform transanal rectal drainage for a few days to prevent a 'blowout' of the rectal stump following mucous retention.

9.2.3. Site of anastomosis for restorative procto-colectomy

ECCO statement 9B

When performing pouch surgery, the maximum length of anorectal mucosa between the dentate line and the anastomosis should not exceed 2 cm [EL 4]

A common complication when using a stapling technique to perform an ileo-anal anastomosis is leaving a remnant of anorectal mucosa above the dentate line. This can be a cause of persistent inflammation ['cuffitis'], with pouch dysfunction and a risk of dysplasia or, very rarely, cancer.^{393,566} When well performed, the low-stapled anastomosis seems to have better outcomes, particularly with regard to soiling, faecal leakage, and social restriction.^{567,568}

Further information on anastomotic technique and site in case of neoplasia complicating colitis can be found in Supplemental material, available as Supplementary data at *ECCO-JCC* online.⁵⁶⁹⁻⁵⁷²

9.2.4. Role of covering ileostomy for restorative procto-colectomy

ECCO statement 9C

A covering loop ileostomy is generally recommended when performing a restorative procto-colectomy for ulcerative colitis [EL 3]

One of the main complications of IPAA surgery is the occurrence of a leak at the suture line of the anastomosis or pouch. This is also a complication that is most likely to compromise the clinical and functional outcomes of the operation. Whether the consequences of a leak can be ameliorated by a covering ileostomy or not is still under debate.^{573,574} However, there is evidence that defunctioning the distal anastomosis may reduce the incidence of a leak.⁵⁷⁵ Nevertheless, it might be clear during pouch surgery that the morbidity associated with a stoma does not justify its use [e.g. when there is a thick abdominal wall and a short small bowel mesentery], as long as no problems have occurred when constructing the anastomosis.⁵⁷⁶⁻⁵⁷⁹

9.2.5. Number of procedures to maintain competency

ECCO statement 9D

Pouches should be performed in specialist referral centres. High-volume centres have lower complication rates and higher rates of pouch salvage following complications [EL 4]

It has been shown that institutions where a larger number of complex surgical procedures that demand sophisticated perioperative care are performed, have better outcomes,⁵⁸⁰ which is also true for pouch surgery.⁵⁸¹ Moreover, it is clear that high-volume institutions manage adverse events better, which leads to better pouch salvage in the face of complications.⁵⁸² Therefore, and if available, ileo-anal pouch surgery should be conducted in high-volume specialist institutions. The definition of 'high-volume' remains open for debate.

9.2.6. Salvage surgery for pouches

Lifetime failure rates of IPAA are approximately 15%. Failure implies an ileostomy for an indefinite period, with or without pouch excision. Failures are usually due to septic complications or persistent pouch dysfunction, although they can also be the result of misdiagnosed Crohn's disease with fistulation or of refractory pouchitis. Before deciding that a pouch has failed, the option of salvage surgery [either as a corrective procedure or as pouch reconstruction] has to be considered. Such surgery must be undertaken by colorectal surgeons with special expertise in this area, and patients' opinions and preferences should be heard. Reported series of pouch-rescue surgery report a salvage rate above 50% and a still acceptable functional outcome.^{583–586} As in pouch surgery, pouch salvage surgery should be performed in units with expertise and a substantial case volume load, although the definition of 'substantial case volume' remains debatable.

9.3. Follow-up

9.3.1. General pouch follow-up

ECCO statement 9E

Early pouchoscopy is recommended in symptomatic patients with pouch dysfunction, in order to distinguish between pouchitis and other conditions [EL 4]

IPAA may be followed by signs and symptoms related to pouchitis [occurring in up to 50% of patients at 10 years of follow-up] or to other conditions [irritable pouch syndrome, Crohn's disease of the pouch, ischaemic pouch, CMV or *C. difficile* infection].^{587–589} Timing of clinical follow-up is adjusted to the development of these conditions, and no standardised schedule is currently available. In patients with signs and symptoms compatible with pouchitis [liquid stools, urgency, tenesmus, pelvic discomfort, or electrolyte imbalance], pouchoscopy should be performed in order to discriminate between pouchitis and the other conditions listed above.⁵⁹⁰ The timing of the endoscopic follow-up should be adjusted to each patient's specific condition.⁵⁹¹

9.3.2. Pouch surveillance

ECCO statement 9F

Annual pouchoscopy is recommended in patients with risk factors such as neoplasia and primary sclerosing cholangitis. No specific pouch follow-up protocol is required in asymptomatic patients [EL 3]

A systematic review of dysplasia after restorative procto-colectomy has reported prevalence rates of 0.15 [range: 0–4.49], 0.98 [range: 0–15.62], and 1.23 [range: 0–25.28 per cent] for HGD, LGD, and indefinite dysplasia, respectively.^{588,592} Dysplasia was equally frequent in the pouch and rectal cuff or anal transitional zone. Dysplasia and cancer identified before or at operation seemed to be significant predictors for the development of pouch dysplasia. Data from this systematic review have been confirmed by others, indicating that even if the indication for colectomy was dysplasia or cancer, the risk of having dysplasia in the rectal cuff or pouch remains very low.^{593,594} No specific follow-up is therefore recommended after restorative procto-colectomy in the absence of risk factors.

9.4. Fertility and delivery in patients with a restorative procto-colectomy

9.4.1. Impact of pelvic surgery on fecundity

ECCO statement 9G

In a fertile female patient, alternative surgical options such as subtotal colectomy and end ileostomy or ileo-rectal anastomosis should be discussed with the patient, because fecundity is at risk after ileal-pouch anal anastomosis [EL3]. A laparoscopic approach is associated with better preservation of female fertility and is preferred [EL3]

Active UC is associated with poor sexual function. Two prospective studies demonstrated an improvement in sexual function in both genders 12 months after IPAA when compared with preoperative levels.^{429,595} On the other hand, it has been convincingly demonstrated in three cohort studies that female fecundity is reduced after an IPAA.^{596–599} This reduction is most likely associated with adhesions affecting the fallopian tubes.⁶⁰⁰ The magnitude of this problem is under debate, with one study showing more than 70% of fecundity reduction, whereas others point towards approximately 30%. Growing evidence suggests that laparoscopic IPAA is technically feasible and may limit the negative consequences as to female fecundity.^{601–604}

Interestingly, data from a study on patients with familial adenomatous polyposis have compared the fecundity reduction in women after an ileo-rectal anastomosis [IRA] or after an IPAA, and have shown that IRA carries no associated reduction in fecundity.^{605,606} Again, this appears to be because an IRA does not induce pelvic adhesions to the same extent as an IPAA. Furthermore, there is evidence that IRA provides a safe and functionally acceptable outcome.^{607,608}

In male patients, retrograde ejaculation and erectile dysfunction are the main, but still rare, sexuality- and fertility-related complications that may occur after an IPAA. Both complications are avoided when an IRA is chosen.⁶⁰⁹ When making the decision on the type of surgical approach, concern about IRA should be considered [see section 9.5.3].

Information on mode of delivery for patients with restorative procto-colectomy can be found in Supplementary materials, available as Supplementary data at *ECCO-JCC* online.^{16,610–617}

9.5. Surgical choices in addition to restorative procto-colectomy

9.5.1. Age

ECCO statement 9H

There is no age limit for performing an ileal-pouch anal anastomosis as long the patient retains good anal sphincter function [EL 5]

IPAA may carry a higher risk for comorbidity in patients aged > 65 years. Still, the procedure is apparently safe and effective in this age group, and remains the surgical technique of choice.⁶¹⁸ However, an increased frequency of long-term complications [e.g. pouchitis, anastomotic stricture] has been reported to occur in elderly patients who undergo IPAA.⁶¹⁹ Deterioration in pouch function with faecal incontinence occurs with advancing age, and this may be more

pronounced in the elderly.^{620,621} Nevertheless, patients aged over 65 years, who have undergone an IPAA, seem to retain a good quality of life.⁶²²

9.5.2. Continent ileostomy

Kock's pouch⁶²³ is an alternative to conventional end-ileostomy after a failed IPAA, for patients who are not candidates for IPAA [due to sphincter injury, for instance], and for those in whom an ileostomy represents considerable problems [e.g. leakage, skin problems, etc.]. Many surgeons have discredited the Kock's pouch procedure given its elevated rate of reoperation, as approximately half of the patients will need reoperation, with nipple valve sliding being the most common indication. Currently however, most series present a 10-year continent pouch survival of around 90%.^{624,625} Quality of life with a Kock's pouch seems superior to that following an end-ileostomy. According to a study from the Cleveland Clinic, patients with an end-ileostomy were more than twice as likely to report social, work, and sexual restrictions as those who underwent a Kock's continent ileostomy.⁶²⁴

9.5.3. Ileo-rectal anastomosis

ECCO statement 9I

Under optimal circumstances, ileo-rectal anastomosis is a reasonable alternative to ileal-pouch anal anastomosis [EL5]. Advantages such as lower morbidity and preserved female fecundity need to be weighed against the need for rectal surveillance and subsequent proctectomy in 50% of cases [EL3]

The reluctance of many surgeons to perform an IRA in UC patients⁶²⁶ is justified by the good long-term functional outcome that follows an IPAA compared with the unpredictable functional outcome after an IRA in a noncompliant and inflamed rectum, as well as by the fear of a subsequent rectal cancer. IRA is a less complex procedure with lower morbidity rates and with reasonable clinical results in highly selected patients. Patients considered for IRA are those that present a relatively spared rectum [or a healed rectum under medical therapy], good rectal compliance, and normal sphincter tone. In these patients, defaecation habits are almost the same as after an IPAA procedure, although urgency seems to be more common in the IRA published series [22–33%].⁶⁰⁷ Urgency is the most common cause of IRA failure. The reported probability of having a functioning IRA ranges from 74% to 84% at 10 years and from 46% to 69% at 20 years.^{626,627} Surveillance of the retained rectum is necessary.¹³

9.5.4. Non-inflammatory pouch dysfunction and pouch failure

ECCO statement 9J

Non-inflammatory causes of pouch dysfunction include pouch-anal stricture, pouch fistula, problems with pouch capacity, efferent limb dysfunction [S-pouch], retained rectal stump, and chronic pre-sacral sepsis. Deciding on appropriate management requires discussion in a multi-disciplinary team setting [EL5]

Detailed information on non-inflammatory pouch dysfunction can be found in Supplementary material, available as Supplementary data at ECCO/JCC online.^{583,586,588,628–637}

9.6. Surgery and medication

9.6.1. Perioperative prednisolone

Uncontrolled and retrospective studies indicate that patients taking more than 20 mg of prednisolone for > 6 weeks have an increased risk of short-term surgical complications.^{638–642} These studies have shown a five-fold risk of infectious complications and an increased risk of short-term postoperative, pouch-specific complications. Therefore, steroids should be weaned before surgery. If weaning is not possible, then pouch construction should be postponed. All recommendations regarding the rate of steroid reduction after colectomy for acute severe colitis are arbitrary but should avoid acute steroid withdrawal [Addisonian crisis], which in its most severe form is characterised by hypotension, hyponatraemia, and hypoglycaemia. Milder symptoms may be interpreted as a slower than normal recovery from surgery. The rate of tapering depends on the dose and duration of steroids preceding to surgery. For patients who have been taking steroids > 6 months, a dose reduction of 1 mg/week over a period of several months might be necessary.

9.6.2. Perioperative thiopurines / calcineurin inhibitors

ECCO statement 9K

Preoperative thiopurines or ciclosporine do not increase the risk of postoperative complications [EL3]

Thiopurines^{643–645} and ciclosporine^{557,643–646} do not increase the risk of postoperative complications after colectomy. The data for tacrolimus are still very scarce.^{646,647}

9.6.3. Perioperative infliximab

TNF is a critical component of the immune response, and its inhibition by IFX or other agents can theoretically lead to serious postoperative complications. An enlarging number of studies that investigated the risk of IFX-associated postoperative complications yield conflicting results. One of these studies, a meta-analysis⁶⁴⁸ of five studies including a total of 706 patients, specifically looking at UC patients,^{638,649–652} reported that preoperative IFX increased the total number of short-term [30 days] postoperative complications [OR: 1.80; 95% CI: 1.12–2.87]. Although this analysis lacked the power needed to assess the nature of these complications, it did show a trend towards increased postoperative infections [OR: 2.24; 95% CI: 0.63–7.95] but not non-infectious complications [OR: 0.85; 95% CI: 0.50–1.45] in those treated with IFX before surgery. Studies published thereafter failed to report an increased rate of IFX-associated complications following procto-colectomy.^{653–655} As nearly all data on this subject come from observational studies rather than from randomised controlled trials, there might be significant bias influencing the results. A study from the Mayo Clinic has shown that postoperative anastomotic leaks and pouch-specific and infectious complications were more common in IFX-treated patients than among those who were not prescribed IFX.^{649,650} After adjustment for concomitant therapy and severity of colitis, IFX was the only factor independently associated with infectious complications. Likewise, a more recently published study suggested that patients with previous anti-TNF use had a higher rate of pelvic sepsis after one-stage IPAA.⁶⁵⁶ Conversely, a large Danish registry including more than 1200 UC patients who underwent a procto-colectomy did not report a significant increase in complications after surgery for previously IFX-exposed patients.⁶⁵⁷

The severity of disease and the sequential use of ciclosporine may also influence the postoperative IFX-associated risk. Patients with less severe forms of the disease and low CRP levels seem to benefit most from IFX therapy,^{649,658–660} and there is particular concern that emergency colectomy within a few weeks of IFX may be associated with more septic complications.

Several studies report the efficacy and safety of ciclosporine and IFX as sequential rescue therapy in patients with steroid-refractory UC.^{651,661–663} Overall, up to one-third of patients achieve short-term remission, and up to two-thirds avoid short-term colectomy.^{662,663} These rates appear to be similar between patients receiving IFX after ciclosporine failure, and patients receiving ciclosporine after IFX failure. However, 16% of all patients experienced serious adverse events including sepsis, with fatal outcomes and herpetic oesophagitis.^{661,662} There is no clear evidence on whether the risk of infectious complications is dependent on the drug sequence although theoretically IFX after ciclosporine should be safer, as ciclosporine has a much shorter half-life. Although some studies suggest a similar complication rate to that reported with IFX or ciclosporine alone,^{662,663} the risk/benefit ratio of sequential rescue therapy has to be considered carefully in selected patients only, and cannot be recommended routinely. This seems to be especially true if ciclosporine is given as the second rescue therapy after IFX failure. As long as the data on perioperative use of anti-TNF agents remain conflicting, the standing recommendation is to not perform a single stage procto-colectomy with ileo-anal pouch construction in anti-TNF treated patients.

Section 10. Pouchitis

10.1. General

Procto-colectomy with an IPAA is the procedure of choice for most UC patients who require colectomy.⁵⁸⁷ Pouchitis is a non-specific inflammation of the ileal reservoir and is the most common complication after an IPAA for UC.^{588–594} Its frequency is related to the follow-up duration, occurring in up to 50% of patients 10 years after IPAA.^{587,588,590–594,664,665} The cumulative incidence of pouchitis in patients with an IPAA following familial adenomatous polyposis is much lower, ranging from 0% to 10%,^{666–668} but reasons for the higher frequency of pouchitis in UC patients remain unknown. Moreover, whether pouchitis develops more commonly within the initial years after IPAA or whether the risk increases continuously with follow-up remains undefined.

ECCO statement 10A

The diagnosis of pouchitis requires the presence of symptoms, together with characteristic endoscopic and histological abnormalities [EL3]. Extensive ulcerative colitis, primary sclerosing cholangitis, being a non-smoker, pANCA-positive serology, and non-steroidal anti-inflammatory drug use are possible risk factors for pouchitis [EL3]

10.1.1. Symptoms

After procto-colectomy with IPAA, daily median stool frequency is four to eight bowel movements,^{587,588,590,591,623,669} with about 700 ml of semi-formed/liquid stool passed per day,^{588,623,669} compared with a volume of 200 ml/day in healthy subjects. Symptoms related to pouchitis include increased stool frequency and liquidity, abdominal cramping, urgency, tenesmus, and pelvic discomfort.^{588,624} Rectal bleeding, fever, and EIM may also occur. Rectal bleeding, however, is more often related to inflammation of the rectal cuff [see section 10.4]⁶²⁵ than to pouchitis. Faecal incontinence may occur in the

absence of pouchitis after IPAA, but is more common in patients with pouchitis. Symptoms of pouch dysfunction in patients with IPAA may be caused by conditions other than pouchitis, including Crohn's disease of the pouch,^{670–672} cuffitis,⁶²⁵ and an irritable pouch,⁶⁷³ among other conditions. This is why the diagnosis depends on endoscopic and histological findings in conjunction with symptoms.

10.1.2. Endoscopy ['pouchoscopy']

Pouchoscopy and pouch mucosal biopsy should be performed in patients with symptoms compatible with pouchitis, in order to confirm the diagnosis.^{624,674} Patients with an ileo-anal pouch occasionally have a stricture at the pouch-anal anastomosis, so a gastroscope rather than a colonoscope is preferred. Progression into the afferent ileal limb should always be attempted. Endoscopic findings compatible with pouchitis include diffuse erythema, which may be patchy, unlike that observed in UC. Characteristic endoscopic findings also include oedema, granularity, friability, spontaneous or contact bleeding, loss of vascular pattern, mucous exudates, haemorrhage, erosions, and ulceration.⁶⁷⁰ Erosions and/or ulcers along the staple line do not necessarily indicate pouchitis.^{671,675,676} Biopsies should be taken from the pouch mucosa and from the afferent limb above the pouch, but not along the staple line.

10.1.3. Histopathology of pouchitis

Additional information on the histopathology of pouchitis can be found in Supplementary material, available as Supplementary data at ECCO-JCC online.^{675–680}

10.1.4. Differential diagnosis

The clinical history and biopsies help discriminate between pouchitis, ischaemia, Crohn's disease, and other rare forms of pouch dysfunction such as collagenous pouchitis and *C. difficile* or CMV pouchitis.^{683–685} Secondary pouchitis, caused by pelvic sepsis, usually causes focal inflammation and should be considered. Biopsies taken from the ileum above the pouch may reveal pre-pouch ileitis as a cause of pouch dysfunction, although this usually causes visible ulceration that may be confused with Crohn's disease.⁶⁸⁴ The possibility of non-specific ileitis caused by NSAIDs should also be considered.⁶⁸⁵

10.1.5. Risk factors for pouchitis and pouch dysfunction

The aetiology of pouchitis remains unclear. Risk factors, genetic associations, and serological markers of pouchitis suggest that a close interaction between the host immune response and the pouch microbiota plays a relevant role in the aetiology of this idiopathic inflammatory condition.⁶⁸⁶ Reported risk factors for pouchitis include extensive UC,^{587,687} backwash ileitis,⁶⁸⁷ EIM [especially PSC],^{592,672,688} being a non-smoker,¹⁴³ and regular use of NSAIDs.^{685,689} Interleukin-1 receptor antagonist gene polymorphisms⁶⁹⁰ and the presence of pANCA⁶⁹¹ are also associated with pouchitis. Not surprisingly, studies are discordant with regard to the role of each risk factor.⁶⁸² In all, 240 consecutive patients were classified as having healthy pouches [$n = 49$], pouchitis [$n = 61$], Crohn's disease [$n = 39$], cuffitis [$n = 41$], or irritable pouch syndrome [$n = 50$]. The risk of developing pouchitis was increased when the indication for IPAA was dysplasia, when the patient had never smoked, used NSAIDs, or [perhaps surprisingly] had never used anxiolytics.⁶⁸² The risk of a diagnosis of Crohn's disease in the pouch was greatly increased by being a current smoker, and modestly increased with having a pouch of long duration. Cuffitis was associated with symptoms of arthralgia and a younger age. Irritable pouch syndrome is probably under-recognised, although it is a common cause of pouch dysfunction when other causes [including a small volume pouch, incomplete evacuation, and pouch volvulus] have been excluded and investigations are normal. The principal risk factor is the use of antidepressants or anxiolytics, which suggests that

these patients may have had irritable bowel syndrome contributing to gastrointestinal symptoms before pouch surgery.⁶⁸² Similar to irritable bowel syndrome, visceral hypersensitivity has been described in these patients.⁶⁹² The same group has recently shown that various perioperative factors may predict pouchitis. On multivariate analysis, pulmonary comorbidity, disease proximal to the splenic flexure, EIM, and S-pouch reconstruction were associated with pouchitis.⁶⁹³ These risk factors should not preclude procto-colectomy if surgery is appropriate, but should be included in preoperative discussions with the patient and family. Similarly if a patient has PSC, then it is appropriate to discuss the higher risk of pouchitis. These discussions are part of an appropriate management of expectations, and known predictive factors for pouchitis or irritable pouch should not be considered as formal contraindications for pouch surgery.

10.2. Pattern of pouchitis

10.2.1. Acute and chronic pouchitis

On the basis of symptoms and endoscopy, pouchitis can be divided into remission [normal pouch frequency] or active pouchitis [increased bowel frequency with endoscopic appearances and histology consistent with pouchitis].^{624,694} Active pouchitis may then be divided into acute or chronic, depending on the symptom duration. The threshold for chronicity is a symptom duration of > 4 weeks. Up to 10% of patients develop chronic pouchitis requiring long-term treatment, and a small subgroup have pouchitis refractory to medical treatment.⁵⁹⁰ Pouchitis may be classified—according to different perspectives—into: 1] idiopathic versus secondary; 2] in remission versus active; and 3] infrequent [< three episodes/year] versus relapsing [> three episodes/year]. Pouchitis may also be classified based on the response to antibiotic therapy: 1] antibiotic-responsive; 2] antibiotic-dependent [need for continuous antibiotic treatment to maintain remission]; and 3] antibiotic-refractory.⁶⁹⁵

Detailed information on scoring of pouchitis can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{675,694,696–699}

10.2.2. Recurrent pouchitis and complications

Pouchitis recurs in more than 50% of patients.^{590,624,692} Patients with recurrent pouchitis can be broadly grouped into three categories: infrequent episodes [< one/year], a relapsing course [one to three episodes/year], or a continuous course. Pouchitis may further be termed treatment responsive or refractory, based on response to antibiotic monotherapy.^{665,700} Although these distinctions are largely arbitrary, they help both patients and physicians when considering management options to alter the pattern of pouchitis. Complications of pouchitis include abscesses, fistulae, stenosis of the pouch-anal anastomosis, and adenocarcinoma of the pouch.^{594,681,694} The latter complication is exceptional and almost only occurs when there is pre-existing dysplasia or carcinoma in the original colectomy specimen.

10.3. Medical treatment

10.3.1. Acute pouchitis: antibiotics

ECCO statement 10B

The majority of patients respond to metronidazole or ciprofloxacin, although the optimum modality of treatment is not clearly defined [EL2]. Side effects are less frequent using ciprofloxacin [EL2]. Antidiarrhoeal drugs may reduce the number of daily liquid stools, independently of pouchitis [EL5]

Treatment of pouchitis is largely empirical and only small placebo-controlled trials have been conducted. Antibiotics are the mainstay of treatment, with metronidazole and ciprofloxacin the most common initial approaches, often resulting in a rapid response.⁷⁰¹ However, randomised trials of both metronidazole and ciprofloxacin are small.^{590,702} Metronidazole and ciprofloxacin have been compared in a small randomised trial.⁶⁹⁶ Seven patients received ciprofloxacin 1 g/day, and nine received metronidazole 20 mg/kg/day, for a period of 2 weeks. Both antibiotics significantly decreased the Perianal Disease Activity Index [PDAI] score, but there was a significantly greater benefit with ciprofloxacin compared with metronidazole in terms of the total PDAI [$p = 0.002$], symptom score [$p = 0.03$], and endoscopic score [$p = 0.03$], as well as fewer adverse events [33% of metronidazole-treated patients reported side effects, but none of those who were receiving ciprofloxacin]. For the treatment of acute pouchitis [four randomised controlled trials, five agents], ciprofloxacin was more effective at inducing remission than metronidazole. Neither rifaximin nor *Lactobacillus plantarum* GG were more effective than placebo, whereas budesonide enemas and metronidazole were equally effective for inducing remission. In a non-randomised, non-controlled, open-label trial, a highly concentrated probiotic preparation [VSL#3] was shown to be effective in the treatment of mildly active pouchitis.^{703,704}

10.3.2. Chronic pouchitis

ECCO statement 10C

In chronic pouchitis a combination of two antibiotics is effective [EL3]. Oral budesonide, oral beclomethasone dipropionate [EL3], and topical tacrolimus [EL3] are alternatives. Infliximab is effective for the treatment of chronic refractory pouchitis [EL4]. Adalimumab may represent an alternative treatment in patients refractory to infliximab [EL4]

For patients who have persistent symptoms, alternative diagnoses should be considered. Approximately 10–15% of patients with acute pouchitis develop chronic pouchitis, which may be ‘treatment responsive’ or ‘treatment refractory’ to single antibiotic therapy.⁵⁸⁸ Patients with chronic, refractory pouchitis do not respond to conventional therapy and often have ongoing symptoms. This is a common cause of pouch failure. Combination antibiotic therapy or oral budesonide may be effective.^{704–709} More recently, oral beclomethasone dipropionate has been shown to be effective in chronic refractory pouchitis. Ten consecutive patients with active pouchitis, not responding to 1-month antibiotic treatment, were treated with beclomethasone dipropionate 10 mg/day for 8 weeks. Eight of 10 patients [80%] achieved remission.⁷¹⁰

10.3.3. Acute and chronic refractory pouchitis: other agents

Detailed information on other agents for the treatment of acute and chronic refractory pouchitis can be found in Supplementary material, available as Supplementary data at *ECCO-JCC* online.^{711–721}

10.3.4. Maintenance of remission: probiotics

Once remission has been achieved in chronic pouchitis, treatment with the concentrated probiotic mixture VSL#3 helps to maintain remission. Two double-blind, placebo-controlled studies have shown the high efficacy of VSL#3 [450 billion bacteria of eight different strains/g] to maintain remission in patients with chronic pouchitis.^{722,723} In the Cochrane systematic review, VSL#3 was more effective than placebo in maintaining remission of chronic pouchitis in patients who achieved remission with antibiotics.^{703,724}

10.3.5. Prevention of pouchitis: probiotics

The same probiotic preparation [VSL#3] has been shown to prevent pouchitis within the first year after surgery in a randomised, double-blind, placebo-controlled study. Patients treated with VSL#3 had a significantly lower incidence of acute pouchitis [10%] compared with those treated with placebo [40%] [$p < 0.05$], and experienced a significant improvement in their quality of life.⁷²⁵ A Cochrane systematic review reports that VSL#3 was more effective than placebo for the prevention of pouchitis.^{703,724}

10.4. Cuffitis

Cuffitis can cause pouch dysfunction with symptoms that mimic pouchitis or irritable pouch syndrome especially after double-stapled IPAA [see section 9]. Unlike the irritable pouch syndrome [which may coexist], bleeding is a characteristic feature of cuffitis. Diagnosis can be made by endoscopy, but care has to be taken to examine the cuff of columnar epithelium between the dentate line and pouch-anal anastomosis [section 9.2.3].⁷⁰⁰ In an open-label trial, 14 consecutive patients with cuffitis treated with 5-ASA suppositories, 500 mg twice daily, experienced a reduction in the total Cuffitis Activity Index [derived from the PDAI] from 11.9 ± 3.17 to 6.21 ± 3.19 [$p < 0.001$].⁶²⁵ In addition, the symptom sub-score reduced from 3.24 ± 1.28 to 1.79 ± 1.31 , endoscopy sub-score from 3.14 ± 1.29 to 1.00 ± 1.52 , and histology sub-score from 4.93 ± 1.77 to 3.57 ± 1.39 ; 92% of patients with bloody bowel movements and 70% with arthralgia [a characteristic clinical feature of cuffitis] improved on therapy. No systemic or topical adverse effects were reported.

Disclaimer

The ECCO consensus guidelines are based on an international consensus process. Any treatment decisions are a matter for the individual clinician and should not be based exclusively on the content of the ECCO consensus guidelines. The European Crohn's and Colitis Organisation and/or any of its staff members and/or any consensus contributor may not be held liable for any information published in good faith in the ECCO consensus guidelines.

Conflict of Interest

ECCO has diligently maintained a disclosure policy of potential conflicts of interests [CoI]. The conflict of interest declaration is based on a form used by the International Committee of Medical Journal Editors [ICMJE]. The CoI statement is not only stored at the ECCO Office and the editorial office of JCC but also open to public scrutiny on the ECCO website [<https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.html>], providing a comprehensive overview of potential conflicts of interest of authors.

Acknowledgments

Working groups [lead author shown first]:

WG1: Fernando Magro, Johan Burisch, Jimmy Limdi, Sandro Ardizzone, Cord Langner; WG2: Franck Carbonnel, Dominik Bettenworth, Konstantinos Karmiris, Torsten Kucharzik, Shaji Sebastian, Helen Tavares de Sousa; WG3: Axel Dignass, Tim Raine, Uri Kopylov, Konstantinos Katsanos, Tamas Molnar; WG4: Paolo Gionchetti, Peter Hindryckx, Ailsa Hart, Manuel Barriero de Acosta, Henriette Vind Thaysen; WG5: Florian Rieder, Kristina Gecse, Gianluca Pellino, Edyta Zagórowicz, Alessandro Armuzzi. Reviewers, on behalf of GuiCom: Glen Doherty [Ireland] and Gionata Fiorino [Italy]; and on behalf of the Governing Board: Julian Panes [Spain] and Gerassimos Mantzaris [Greece].

Supplementary Data

Supplementary data are available at [ECCO-JCC](https://www.ecco-ibd.eu) online.

References

- Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. *J Crohns Colitis* 2012;6:965–90.
- Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012;6:991–1030.
- Van Assche G, Dignass A, Bokemeyer B, et al.; European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *J Crohns Colitis* 2013;7:1–33.
- Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation [ECCO]. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. *J Crohns Colitis* 2008;2:1–23.
- Travis SP, Stange EF, Lémann M, et al.; European Crohn's and Colitis Organisation [ECCO]. European evidence-based consensus on the management of ulcerative colitis: current management. *J Crohns Colitis* 2008;2:24–62.
- Biancone L, Michetti P, Travis S, et al.; European Crohn's and Colitis Organisation [ECCO]. European evidence-based consensus on the management of ulcerative colitis: special situations. *J Crohns Colitis* 2008;2:63–92.
- Harbord M, Annese V, Vavricka SR, et al.; European Crohn's and Colitis Organisation. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *J Crohns Colitis* 2016;10:239–54.
- Annese V, Beaugerie L, Egan L, et al.; ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. *J Crohns Colitis* 2015;9:945–65.
- Panes J, Bounnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *J Crohns Colitis* 2013;7:556–85.
- Bourreille A, Ignjatovic A, Aabakken L, et al.; World Organisation of Digestive Endoscopy [OMED] and the European Crohn's and Colitis Organisation [ECCO]. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. *Endoscopy* 2009;41:618–37.
- Rahier JF, Magro F, Abreu C, et al.; European Crohn's and Colitis Organisation [ECCO]. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014;8:443–68.
- Øresland T, Bemelman WA, Sampietro GM, et al.; European Crohn's and Colitis Organisation [ECCO]. European evidence-based consensus on surgery for ulcerative colitis. *J Crohns Colitis* 2015;9:4–25.
- Annese V, Daperno M, Rutter MD, et al.; European Crohn's and Colitis Organisation. European evidence-based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013;7:982–1018.
- Magro F, Langner C, Driessen A, et al.; European Society of Pathology [ESP]; European Crohn's and Colitis Organisation [ECCO]. European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013;7:827–51.
- Dignass AU, Gasche C, Bettenworth D, et al.; European Crohn's and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. *J Crohns Colitis* 2015;9:211–22.
- van der Woude CJ, Ardizzone S, Bengtson MB, et al.; European Crohn's and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohns Colitis* 2015;9:107–24.
- Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr* 2012;55:340–61.
- Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease [EC-IBD]. *Gut* 1996;39:690–7.

19. Burisch J, Pedersen N, Čuković-Čavka S, *et al.*; EpiCom group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut* 2014;**63**:588–97.
20. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. *J Crohns Colitis* 2013;**7**:322–37.
21. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T; IBSEN Group. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. *Gut* 2013;**62**:368–75.
22. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations [EFCCA] patient survey. *J Crohns Colitis* 2007;**1**:10–20.
23. Silverberg MS, Satsangi J, Ahmad T, *et al.* Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005;**19**:5A–36A.
24. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006;**55**:749–53.
25. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease—colitis indeterminate. *J Clin Pathol* 1978;**31**:567–77.
26. Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalazine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. *Inflamm Bowel Dis* 2006;**12**:537–42.
27. Burisch J, Pedersen N, Cukovic-Cavka S, *et al.*; EpiCom Group. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. *Inflamm Bowel Dis* 2014;**20**:36–46.
28. Solberg IC, Lygren I, Jahnsen J, *et al.*; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort [IBSEN Study]. *Scand J Gastroenterol* 2009;**44**:431–40.
29. Barreiro-de Acosta M, Magro F, Carpio D, *et al.* Ulcerative colitis in Northern Portugal and Galicia in Spain. *Inflamm Bowel Dis* 2010;**16**:1227–38.
30. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. *Gut* 2013;**62**:1795–805.
31. Levine A, Griffiths A, Markowitz J, *et al.* Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011;**17**:1314–21.
32. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955;**2**:1041–8.
33. D'Haens G, Sandborn WJ, Feagan BG, *et al.* A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007;**132**:763–86.
34. Riceoxley JM, Truelove S. Ulcerative colitis—course and prognosis. *Lancet* 1950;**258**:663–6.
35. Peyrin-Biroulet L, Ferrante M, Magro F, *et al.*; Scientific Committee of the European Crohn's and Colitis Organisation. Results from the 2nd scientific workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. *J Crohns Colitis* 2011;**5**:477–83.
36. Daperno M, Castiglione F, de Ridder L, *et al.*; Scientific Committee of the European Crohn's and Colitis Organisation. Results of the 2nd part scientific workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. *J Crohns Colitis* 2011;**5**:484–98.
37. Armuzzi A, Van Assche G, Reinisch W, *et al.* Results of the 2nd scientific workshop of the ECCO [IV]: therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. *J Crohns Colitis* 2012;**6**:492–502.
38. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. *Gut* 2005;**54**:782–8.
39. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. *Gut* 1963;**4**:299–315.
40. Farraye FA, Odze RD, Eaden J, *et al.*; AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010;**138**:738–45.
41. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;**11**:314–21.
42. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010;**105**:501–23; quiz 524.
43. Ekblom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 1990;**323**:1228–33.
44. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH Jr, Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. *Gut* 1991;**32**:167–9.
45. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. *Aliment Pharmacol Ther* 2014;**39**:645–59.
46. Katsanos KH, Vermeire S, Christodoulou DK, *et al.*; EC-IBD Study Group. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. *Digestion* 2007;**75**:113–21.
47. Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. *Scand J Gastroenterol* 1987;**22**:459–62.
48. Gyde SN, Prior P, Allan RN, *et al.* Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. *Gut* 1988;**29**:206–17.
49. Rutter M, Saunders B, Wilkinson K, *et al.* Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004;**126**:451–9.
50. Gupta RB, Harpaz N, Itzkowitz S, *et al.* Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. *Gastroenterology* 2007;**133**:1099–105; quiz 1340–1.
51. Rubin DT, Huo D, Kinnucan JA, *et al.* Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. *Clin Gastroenterol Hepatol* 2013;**11**:1601–8.e1.
52. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. *Scand J Gastroenterol* 1996;**31**:260–6.
53. Meucci G, Vecchi M, Astegiano M, *et al.* The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali [GSMII]. *Am J Gastroenterol* 2000;**95**:469–73.
54. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, *et al.* The natural history of pediatric ulcerative colitis: a population-based cohort study. *Am J Gastroenterol* 2009;**104**:2080–8.
55. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. *Gastroenterology* 1994;**107**:3–11.
56. Høie O, Wolters F, Riis L, *et al.*; European Collaborative Study Group of Inflammatory Bowel Disease [EC-IBD]. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. *Am J Gastroenterol* 2007;**102**:1692–701.
57. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. *Gastroenterology* 2007;**132**:516–26.
58. Meyers S, Janowitz HD. The 'natural history' of ulcerative colitis: an analysis of the placebo response. *J Clin Gastroenterol* 1989;**11**:33–7.
59. Jess T, Riis L, Vind I, *et al.* Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. *Inflamm Bowel Dis* 2007;**13**:481–9.
60. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? *Gut* 1991;**32**:174–8.
61. Fagan EA, Dyck RF, Maton PN, *et al.* Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. *Eur J Clin Invest* 1982;**12**:351–9.
62. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic,

- histologic, and radiographic activity in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;11:707–12.
63. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* 2007;133:423–32.
 64. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. *Gut* 1996;38:905–10.
 65. Herrlinger KR, Dittmann R, Weitz G, et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. *Inflamm Bowel Dis* 2004;10:229–33.
 66. Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. *Nat Clin Pract Gastroenterol Hepatol* 2005;2:580–6.
 67. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. *Dig Liver Dis* 2003;35:642–7.
 68. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. *Am J Gastroenterol* 2003;98:1309–14.
 69. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. *Clin Chim Acta* 2007;381:63–8.
 70. Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. *Scand J Gastroenterol* 1992;27:139–42.
 71. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. *Gut* 2007;56:1706–13.
 72. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. *Inflamm Bowel Dis* 2009;15:1190–8.
 73. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. *Am J Gastroenterol* 2007;102:803–13.
 74. Schoepfer AM, Trummel M, Seeholzer P, et al. Calprotectin helps to distinguish between an acute IBD episode and symptoms related to IBS. *Inflamm Bowel Dis* 2008;14:1432–9.
 75. Schoepfer AM, Beglinger C, Straumann A, Trummel M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. *Inflamm Bowel Dis* 2009;15:1851–8.
 76. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. *Inflamm Bowel Dis* 2013;19:332–41.
 77. Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? *Pract Gastroenterol* 2010;30:17–20.
 78. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. *Gastroenterology* 1991;100:1590–6.
 79. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. *Rev Gastroenterol Disord* 2004;4:167–74.
 80. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. *Gut* 1998;42:788–91.
 81. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. *Gastroenterology* 1998;115:822–9.
 82. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. *Am J Gastroenterol* 2001;96:730–4.
 83. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. *Gastroenterology* 2002;122:1242–7.
 84. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. *Dig Dis Sci* 2004;49:1280–6.
 85. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterology* 2005;128:2020–8.
 86. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. *Gastroenterology* 2006;131:366–78.
 87. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin [CBir1] phenotypic and genetic Crohn's disease associations. *Inflamm Bowel Dis* 2007;13:524–30.
 88. Liu JZ, van Sommeren S, Huang H, et al.; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015;47:979–86.
 89. Jostins L, Ripke S, Weersma RK, et al.; International IBD Genetics Consortium [IBDGC]. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012;491:119–24.
 90. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. *Gastroenterology* 2007;133:1327–39.
 91. Goyette P, Boucher G, Mallon D, et al.; International Inflammatory Bowel Disease Genetics Consortium; Australia and New Zealand IBDGC; Belgium IBD Genetics Consortium; Italian Group for IBD Genetic Consortium; NIDDK Inflammatory Bowel Disease Genetics Consortium; United Kingdom IBDGC; Wellcome Trust Case Control Consortium; Quebec IBD Genetics Consortium. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. *Nat Genet* 2015;47:172–9.
 92. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006;314:1461–3.
 93. Stoll M, Corneliusen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. *Nat Genet* 2004;36:476–80.
 94. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. *Pharmacol Res* 2013;76:1–8.
 95. McGovern DP, Gardet A, Törkvist L, et al.; NIDDK IBD Genetics Consortium. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet* 2010;42:332–7.
 96. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010;42:1118–25.
 97. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011;43:246–52.
 98. Bank S, Andersen PS, Burisch J, et al. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish Cohort. *PLoS One* 2015;10:e0145302.
 99. Rivas MA, Graham D, Sulem P, et al.; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. *Nat Commun* 2016;7:12342.
 100. Ellinghaus D, Jostins L, Spain SL, et al.; International IBD Genetics Consortium [IBDGC]; International Genetics of Ankylosing Spondylitis Consortium [IGAS]; International PSC Study Group [IPSCSG]; Genetic Analysis of Psoriasis Consortium [GAPC]; Psoriasis Association Genetics Extension [PAGE]. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet* 2016;48:510–8.
 101. Gordon H, Trier Moller F, Andersen V, Harbord M. Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies. *Inflamm Bowel Dis* 2015;21:1428–34.
 102. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126:1504–17.

103. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. *Clin Gastroenterol Hepatol* 2005;3:11–24.
104. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. *Dig Dis Sci* 1982;27:533–7.
105. Both H, Torp-Pedersen K, Kreiner S, Hendriksen C, Binder V. Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. *Scand J Gastroenterol* 1983;18:987–91.
106. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. *Gut* 1986;27:92–5.
107. Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. *Gut* 1988;29:342–5.
108. Drossman DA, Li Z, Leserman J, Patrick DL. Ulcerative colitis and Crohn's disease health status scales for research and clinical practice. *J Clin Gastroenterol* 1992;15:104–12.
109. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. *Eur J Gastroenterol Hepatol* 1997;9:353–9.
110. Rath HC, Andus T, Caesar I, Schölmerich J. Initial symptoms, extra-intestinal manifestations and course of pregnancy in chronic inflammatory bowel diseases. *Med Klin [Munich]* 1998;93:395–400.
111. Seo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. *Am J Gastroenterol* 1998;93:2124–9.
112. Illescas L, García L, Faggioni F, Velasco L. Ulcerative colitis: a 52 years retrospective study. *Rev Gastroenterol Peru* 1999;19:116–23.
113. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. *Gastroenterology* 2004;126:1518–32.
114. Collins PD, Mpfu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Database Syst Rev* 2006;CD000279.
115. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. *Gastroenterology* 1999;116:1464–86.
116. Hamzaoglu I, Hodin RA. Perianal problems in patients with ulcerative colitis. *Inflamm Bowel Dis* 2005;11:856–9.
117. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007;369:1641–57.
118. Henriksen M, Jahnsen J, Lygren I, et al.; Ibsen Study Group. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study [the IBSEN Study]. *Scand J Gastroenterol* 2006;41:1037–43.
119. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. *World J Gastroenterol* 2005;11:7227–36.
120. Isene R, Bernklev T, Høie O, et al.; EC-IBD Study Group. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort. *Scand J Gastroenterol* 2015;50:300–5.
121. Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. *World J Gastroenterol* 2014;20:17463–7.
122. Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. *Digestion* 2014;90:122–9.
123. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2014;40:3–15.
124. Moris G. Inflammatory bowel disease: an increased risk factor for neurologic complications. *World J Gastroenterol* 2014;20:1228–37.
125. Wilson MZ, Connelly TM, Tinsley A, Hollenbeak CS, Koltun WA, Messaris E. Ulcerative colitis is associated with an increased risk of venous thromboembolism in the postoperative period: the results of a matched cohort analysis. *Ann Surg* 2015;261:1160–6.
126. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. *Am J Gastroenterol* 2007;102:174–86.
127. Vegh Z, Golovics PA, Lovasz BD, et al. Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. *Scand J Gastroenterol* 2015;50:306–11.
128. Isene R, Bernklev T, Høie O, et al.; EC-IBD Study Group. Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort. *Scand J Gastroenterol* 2014;49:820–5.
129. Scoville EA, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. *Inflamm Bowel Dis* 2014;20:631–6.
130. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. *Gastroenterology* 2014;146:835–48.e6.
131. Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;37:953–62.
132. Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. *World J Gastroenterol* 2014;20:4857–72.
133. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. *Aliment Pharmacol Ther* 2006;24:2–10.
134. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. *Am J Gastroenterol* 2015;110:564–71.
135. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo Clin Proc* 2006;81:1462–71.
136. Lunney PC, Leong RW. Review article: Ulcerative colitis, smoking and nicotine therapy. *Aliment Pharmacol Ther* 2012;36:997–1008.
137. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. *Am J Gastroenterol* 2012;107:1399–406.
138. To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. *Aliment Pharmacol Ther* 2016;44:117–26.
139. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. *Am J Gastroenterol* 2001;96:2113–6.
140. Birrenbach T, Böcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. *Inflamm Bowel Dis* 2004;10:848–59.
141. Rudra T, Motley R, Rhodes J. Does smoking improve colitis? *Scand J Gastroenterol Suppl* 1989;170:61–3; discussion 66–8.
142. Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. *Gastroenterology* 1996;110:1496–502.
143. Merrett MN, Mortensen N, Kettlewell M, Jewell DO. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. *Gut* 1996;38:362–4.
144. Joelsson M, Benoni C, Oresland T. Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis? *Scand J Gastroenterol* 2006;41:929–33.
145. Frisch M, Pedersen BV, Andersson RE. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. *BMJ* 2009;338:b716.
146. Rutgeerts P, D'Haens G, Hiele M, Geboes K, Vantrappen G. Appendectomy protects against ulcerative colitis. *Gastroenterology* 1994;106:1251–3.
147. Frisch M, Johansen C, Mellekjaer L, et al. Appendectomy and subsequent risk of inflammatory bowel diseases. *Surgery* 2001;130:36–43.
148. Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. *Inflamm Bowel Dis* 2002;8:277–86.

149. Cosnes J, Carbonnel F, Beaugerie L, Blain A, Reijasse D, Gendre JP. Effects of appendectomy on the course of ulcerative colitis. *Gut* 2002;51:803–7.
150. Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendectomy on onset and severity of ulcerative colitis and Crohn's disease. *Gut* 2002;51:808–13.
151. Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. *Gut* 2004;53:973–9.
152. Gardenbroek TJ, Pinkney TD, Sahami S, et al. The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial [NTR2883] and the ACCURE-UK trial: a randomised external pilot trial [ISRCTN56523019]. *BMC Surg* 2015;15:30.
153. Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? *Aliment Pharmacol Ther* 2004;20:1035–43.
154. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2006;4:196–202.
155. Korzenik JR, Podolsky DK. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2006;4:157–9.
156. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. *Clin Gastroenterol Hepatol* 2006;4:203–11.
157. Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. *Scand J Gastroenterol* 2015;50:255–63.
158. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. *Aliment Pharmacol Ther* 2003;17:1371–80.
159. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2004;53:V1–16.
160. Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* 2004;1:26–31.
161. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007;448:427–34.
162. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. *Am J Gastroenterol* 2006;101:993–1002.
163. García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. *Aliment Pharmacol Ther* 2005;22:309–15.
164. Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B; IBSEN Study Group. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. *Am J Gastroenterol* 2007;102:1955–63.
165. Travis SP, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J, Sutherland LR, editors. *Inflammatory Bowel Diseases*. London: Churchill Livingstone; 2003: 169–81.
166. Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. *Clin Gastroenterol Hepatol* 2007;5:602–8; quiz 525.
167. Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. *J Clin Gastroenterol* 1988;10:41–5.
168. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. *Dig Dis Sci* 2007;52:2063–8.
169. Langner C, Magro F, Driessen A, et al.; European Society of Pathology; European Crohn's and Colitis Foundation. The histopathological approach to inflammatory bowel disease: a practice guide. *Virchows Arch* 2014;464:511–27.
170. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjö Dahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. *Eur J Gastroenterol Hepatol* 1998;10:831–5.
171. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. *J Crohns Colitis* 2015;9:156–63.
172. Brown WJ, Hudson MJ, Patrick S, et al. Search for enteric microbial pathogens in patients with ulcerative colitis. *Digestion* 1992;53:121–8.
173. Weber P, Koch M, Heizmann WR, Scheurlen M, Jess H, Hartmann F. Microbial superinfection in relapse of inflammatory bowel disease. *J Clin Gastroenterol* 1992;14:302–8.
174. Rolny P, Järnerot G, Möllby R. Occurrence of *Clostridium difficile* toxin in inflammatory bowel disease. *Scand J Gastroenterol* 1983;18:61–4.
175. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of *Clostridium difficile* infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008;103:1443–50.
176. Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of *Clostridium difficile* infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. *Dig Liver Dis* 2014;46:1086–92.
177. Landsman MJ, Sultan M, Stevens M, Charabaty A, Mattar MC. Diagnosis and management of common gastrointestinal tract infectious diseases in ulcerative colitis and Crohn's disease patients. *Inflamm Bowel Dis* 2014;20:2503–10.
178. Issa M, Vijayapal A, Graham MB, et al. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007;5:345–51.
179. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of *Clostridium difficile* infection in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007;5:339–44.
180. Masclee GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ. Is *clostridium difficile* associated with relapse of inflammatory bowel disease? results from a retrospective and prospective cohort study in the Netherlands. *Inflamm Bowel Dis* 2013;19:2125–31.
181. Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC. Impact of *Clostridium difficile* colitis on 5-year health outcomes in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2012;36:1032–9.
182. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. *Gut* 2004;53:673–7.
183. Minami M, Ohta M, Ohkura T, et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. *World J Gastroenterol* 2007;13:754–60.
184. Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. *Am J Gastroenterol* 2007;102:331–7.
185. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:879–84.
186. Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. *Inflamm Bowel Dis* 2004;10:245–50.
187. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. *Scand J Gastroenterol* 2006;41:706–11.
188. Zidar N, Ferkolj I, Tepeš K, et al. Diagnosing cytomegalovirus in patients with inflammatory bowel disease—by immunohistochemistry or polymerase chain reaction? *Virchows Arch* 2015;466:533–9.
189. Shukla T, Singh S, Loftus EV Jr, Bruining DH, McCurdy JD. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with

- Cytomegalovirus: Systematic Review and Meta-analysis. *Inflamm Bowel Dis* 2015;21:2718–25.
190. Riis L, Vind I, Vermeire S, *et al.*; European Collaborative Study Group on Inflammatory Bowel Disease. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. *Inflamm Bowel Dis* 2007;13:24–32.
 191. Joossens S, Daperno M, Shums Z, *et al.* Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. *Clin Chem* 2004;50:1422–5.
 192. Plevy S. Do serological markers and cytokines determine the indeterminate? *J Clin Gastroenterol* 2004;38:S51–6.
 193. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut* 2006;55:426–31.
 194. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. *Aliment Pharmacol Ther* 2002;16:675–81.
 195. Langhorst J, Elsenbruch S, Mueller T, *et al.* Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. *Inflamm Bowel Dis* 2005;11:1085–91.
 196. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:S24–34.
 197. Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. *Clin Biochem* 2012;45:S52–5.
 198. Takashima S, Kato J, Hiraoka S, *et al.* Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. *Am J Gastroenterol* 2015;110:873–80.
 199. Lin JF, Chen JM, Zuo JH, *et al.* Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. *Inflamm Bowel Dis* 2014;20:1407–15.
 200. Vinding KK, Elsberg H, Thorkilgaard T, *et al.* Fecal calprotectin measured by patients at home using smartphones—a new clinical tool in monitoring patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2016;22:336–44.
 201. Markowitz J, Kahn E, Grancher K, Hyams J, Treem W, Daum F. Atypical rectosigmoid histology in children with newly diagnosed ulcerative colitis. *Am J Gastroenterol* 1993;88:2034–7.
 202. Rajwal SR, Puntis JW, McClean P, *et al.* Endoscopic rectal sparing in children with untreated ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2004;38:66–9.
 203. Robert ME, Skacel M, Ullman T, Bernstein CN, Easley K, Goldblum JR. Patterns of colonic involvement at initial presentation in ulcerative colitis: a retrospective study of 46 newly diagnosed cases. *Am J Clin Pathol* 2004;122:94–9.
 204. Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. *Am J Gastroenterol* 1999;94:3258–62.
 205. Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-aminosalicylic acid [5-ASA] therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. *Am J Surg Pathol* 1993;17:869–75.
 206. Park SH, Loftus EV Jr, Yang SK. Appendiceal skip inflammation and ulcerative colitis. *Dig Dis Sci* 2014;59:2050–7.
 207. Byeon JS, Yang SK, Myung SJ, *et al.* Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status. *Inflamm Bowel Dis* 2005;11:366–71.
 208. Ladefoged K, Munck LK, Jorgensen F, Engel P. Skip inflammation of the appendiceal orifice: a prospective endoscopic study. *Scand J Gastroenterol* 2005;40:1192–6.
 209. Yang SK, Jung HY, Kang GH, *et al.* Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: an analysis in relation to medical therapy and disease extent. *Gastrointest Endosc* 1999;49:743–7.
 210. Matsumoto T, Nakamura S, Shimizu M, Iida M. Significance of appendiceal involvement in patients with ulcerative colitis. *Gastrointest Endosc* 2002;55:180–5.
 211. Park SH, Yang SK, Park SK, *et al.* Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. *Can J Gastroenterol Hepatol* 2014;28:125–30.
 212. Haskell H, Andrews CW Jr, Reddy SI, *et al.* Pathologic features and clinical significance of ‘backwash’ ileitis in ulcerative colitis. *Am J Surg Pathol* 2005;29:1472–81.
 213. Abdelrazeq AS, Wilson TR, Leitch DL, Lund JN, Leveson SH. Ileitis in ulcerative colitis: is it a backwash? *Dis Colon Rectum* 2005;48:2038–46.
 214. Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. *Am J Clin Pathol* 2006;126:365–76.
 215. Navaneethan U, Jegadeesan R, Gutierrez NG, *et al.* Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. *Dig Dis Sci* 2013;58:2019–27.
 216. Arrossi AV, Kariv Y, Bronner MP, *et al.* Backwash ileitis does not affect pouch outcome in patients with ulcerative colitis with restorative proctocolectomy. *Clin Gastroenterol Hepatol* 2011;9:981–8.
 217. Gomollón F, Dignass A, Annesse V, *et al.*; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. *J Crohns Colitis* 2017;11:3–25.
 218. Buckell NA, Williams GT, Bartram CI, Lennard-Jones JE. Depth of ulceration in acute colitis: correlation with outcome and clinical and radiologic features. *Gastroenterology* 1980;79:19–25.
 219. Jakobovits SL, Travis SP. Management of acute severe colitis. *Br Med Bull* 2005;75-76:131–44.
 220. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. *Gut* 1975;16:579–84.
 221. Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. *Gut* 1991;32:1535–7.
 222. Criscuoli V, Casà A, Orlando A, *et al.* Severe acute colitis associated with CMV: a prevalence study. *Dig Liver Dis* 2004;36:818–20.
 223. Record CO, Bramble MG, Lishman AH, *et al.* Flexible sigmoidoscopy in outpatients with suspected colonic disease. *Br Med J* 1981;283:1291–2.
 224. Navaneethan U, Kochhar G, Phull H, *et al.* Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. *J Crohns Colitis* 2012;6:470–5.
 225. Carbonnel F, Lavergne A, Lémann M, *et al.* Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. *Dig Dis Sci* 1994;39:1550–7.
 226. Orlandi F, Brunelli E, Feliciangeli G, *et al.* Observer agreement in endoscopic assessment of ulcerative colitis. *Ital J Gastroenterol Hepatol* 1998;30:539–41.
 227. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007;133:412–22.
 228. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. *Am J Dig Dis* 1966;11:847–57.
 229. Ardizzone S, Cassinotti A, Duca P, *et al.* Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. *Clin Gastroenterol Hepatol* 2011;9:483–9.e3.
 230. Meucci G, Fasoli R., Saibeni S., Valpiani D., Gullotta R., Colombo E., *et al.* Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. *Inflamm Bowel Dis* 2012;18:1006–10.
 231. Travis SP, Schnell D, Krzeski P, *et al.* Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity [UCEIS]. *Gut* 2012;61:535–42.
 232. Thia KT, Loftus EV Jr, Pardi DS, *et al.* Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. *Inflamm Bowel Dis* 2011;17:1257–64.
 233. Travis SPL., Schnell D., Krzeski P., Abreu MT., Altman DG., Colombel J-F., *et al.* Reliability and initial validation of the ulcerative colitis endoscopic index of severity. *Gastroenterology* 2013;145:987–95.
 234. Pera A, Bellando P, Caldera D, *et al.* Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. *Gastroenterology* 1987;92:181–5.
 235. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. *Br Med J* 1964;1:89–92.

236. de Dombal FT, Watts JM, Watkinson G, Goligher JC. Local complications of ulcerative colitis. Stricture, pseudopolyps and cancer of the colon and rectum. *Am J Proctol* 1967;18:198–201.
237. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. *Gut* 2012;61:1619–35.
238. Sung J, Ho KY, Chiu HM, Ching J, Travis S, Peled R. The use of Pillcam Colon in assessing mucosal inflammation in ulcerative colitis: a multicenter study. *Endoscopy* 2012;44:754–8.
239. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;317:1625–9.
240. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. *N Engl J Med* 2005;352:2499–507.
241. Parente F, Greco S, Molteni M, et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. *Aliment Pharmacol Ther* 2003;18:1009–16.
242. Hollerbach S, Geissler A, Schiegl H, et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. *Scand J Gastroenterol* 1998;33:1201–8.
243. Maconi G, Ardizzone S, Parente F, Bianchi Porro G. Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis. *Scand J Gastroenterol* 1999;34:1103–7.
244. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. *Am J Gastroenterol* 2010;105:1150–7.
245. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. *Gut* 2004;53:1813–6.
246. Andersen K, Vogt C, Blondin D, et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. *Eur J Radiol* 2006;58:140–6.
247. Feakins RM; British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. *J Clin Pathol* 2013;66:1005–26.
248. Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. *Am J Surg Pathol* 1998;22:983–9.
249. Cross SS, Harrison RF. Discriminant histological features in the diagnosis of chronic idiopathic inflammatory bowel disease: analysis of a large dataset by a novel data visualisation technique. *J Clin Pathol* 2002;55:51–7.
250. Schumacher G, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. *Scand J Gastroenterol* 1994;29:318–32.
251. Seldenrijk CA, Morson BC, Meuwissen SG, Schipper NW, Lindeman J, Meijer CJ. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. *Gut* 1991;32:1514–20.
252. Surawicz CM, Haggitt RC, Husseman M, McFarland LV. Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. *Gastroenterology* 1994;107:755–63.
253. Nostrant TT, Kumar NB, Appelman HD. Histopathology differentiates acute self-limited colitis from ulcerative colitis. *Gastroenterology* 1987;92:318–28.
254. McCormick DA, Horton LW, Mee AS. Mucin depletion in inflammatory bowel disease. *J Clin Pathol* 1990;43:143–6.
255. Bentley E, Jenkins D, Campbell F, Warren B. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. *J Clin Pathol* 2002;55:955–60.
256. Moum B, Ekobom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. *Am J Gastroenterol* 1999;94:1564–9.
257. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. *J Crohns Colitis* 2014;8:1582–97.
258. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. *Gut* 2000;47:404–9.
259. Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. *Inflamm Bowel Dis* 2014;20:564–75.
260. Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L. Comparing histological activity indexes in UC. *Gut* 2015;64:1412–8.
261. Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. *Gut* 2017;66:50–8.
262. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. *Gastroenterology* 2001;120:13–20.
263. Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscopy are predictive of relapse in patients with quiescent ulcerative colitis. *Gut* 2006;55:1768–73.
264. Nishio Y, Ando T, Maeda O, et al. Predictors of relapse in patients with quiescent ulcerative colitis. *Gut* 2006;55:1760–7.
265. Bessisow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. *Am J Gastroenterol* 2012;107:1684–92.
266. Feagins LA, Melton SD, Iqbal R, Dunbar KB, Spechler SJ. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. *Inflamm Bowel Dis* 2013;19:1477–82.
267. Zenlea T, Yee EU, Rosenberg L, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. *Am J Gastroenterol* 2016;111:685–90.
268. Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. *World J Gastroenterol* 2014;20:4980–6.
269. Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. *Clin Gastroenterol Hepatol* 2013;11:991–6.
270. Lemmens B, Arijis I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. *Inflamm Bowel Dis* 2013;19:1194–201.
271. Tursi A, Elisei W, Picchio M, et al. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. *Clin Res Hepatol Gastroenterol* 2015;39:107–13.
272. Mazzuoli S, Guglielmi FW, Antonelli E, Salemm M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. *Dig Liver Dis* 2013;45:969–77.
273. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? *Clin Gastroenterol Hepatol* 2014;12:929–34.e2.
274. Parente F, Cucino C, Bollani S, et al. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role. *Am J Gastroenterol* 2000;95:705–11.
275. Sharif F, McDermott M, Dillon M, et al. Focally enhanced gastritis in children with Crohn’s disease and ulcerative colitis. *Am J Gastroenterol* 2002;97:1415–20.
276. McHugh JB, Gopal P, Greenson JK. The clinical significance of focally enhanced gastritis in children. *Am J Surg Pathol* 2013;37:295–9.
277. Roka K, Roma E, Stefanaki K, Panayotou I, Kopsidas G, Chouliaras G. The value of focally enhanced gastritis in the diagnosis of pediatric inflammatory bowel diseases. *J Crohns Colitis* 2013;7:797–802.
278. Ushiku T, Moran CJ, Lauwers GY. Focally enhanced gastritis in newly diagnosed pediatric inflammatory bowel disease. *Am J Surg Pathol* 2013;37:1882–8.
279. Dejaco C, Oesterreicher C, Angelberger S, et al. Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis. *Endoscopy* 2003;35:1004–8.
280. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. *Inflamm Bowel Dis* 2014;20:936–45.
281. Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in

- Scandinavia: a longitudinal 2-year follow-up study. *Scand J Gastroenterol* 2013;48:1286–93.
282. Ott C, Liebold A, Takses A, Strauch UG, Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. *Gastroenterol Res Pract* 2012;2012:595970.
 283. Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. *World J Gastroenterol* 2009;15:4659–65.
 284. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. *Inflamm Bowel Dis* 2007;13:1545–53.
 285. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. *Clin Chim Acta* 2003;329:9–22.
 286. Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. *Proc Natl Acad Sci U S A* 2007;104:17063–8.
 287. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005;352:1011–23.
 288. Voegelin M, Vavricka SR, Schoepfer AM, et al.; Swiss IBD Cohort Study. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. *J Crohns Colitis* 2010;4:642–8.
 289. Evstatiev R, Marteau P, Iqbal T, et al.; FERG Study Group. FERGlor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. *Gastroenterology* 2011;141:846–53.e1–2.
 290. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. *Am J Gastroenterol* 2009;104:1460–7.
 291. Evstatiev R, Alexeeva O, Bokemeyer B, et al.; FERG Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013;11:269–77.
 292. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. *Digestion* 1999;60:262–7.
 293. Gasché C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. *Ann Intern Med* 1997;126:782–7.
 294. Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. *Eur J Gastroenterol Hepatol* 2006;18:421–5.
 295. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999;340:409–17.
 296. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med* 2013;368:11–21.
 297. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011;106:110–9.
 298. Orchard TR, Wordworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut* 1998;42:387–91.
 299. de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. *J Rheumatol* 2000;27:2860–5.
 300. Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. *J Gastroenterol Hepatol* 2008;23:132–7.
 301. Queiro R, Maiz O, Intxausti J, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. *Clin Rheumatol* 2000;19:445–9.
 302. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361–8.
 303. Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x-rays with magnetic resonance imaging using established and new scoring systems. *Ann Rheum Dis* 2004;63:1046–55.
 304. Puhakka KB, Jurik AG, Schiøttz-Christensen B, et al. MRI abnormalities of sacroiliac joints in early spondyloarthropathy: a 1-year follow-up study. *Scand J Rheumatol* 2004;33:332–8.
 305. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab [Remicade] in a German prospective, open-label, multicenter trial in refractory Crohn's disease. *Am J Gastroenterol* 2002;97:2688–90.
 306. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. *Lancet* 2000;356:1821–2.
 307. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. *Ann Rheum Dis* 2004;63:1664–9.
 308. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. *Ann Rheum Dis* 2003;62:74–6.
 309. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann Rheum Dis* 2006;65:423–32.
 310. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha [infliximab] versus placebo in active spondyloarthropathy. *Arthritis Rheum* 2002;46:755–65.
 311. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. *Ann Rheum Dis* 2008;67:340–5.
 312. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;359:1187–93.
 313. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med* 2002;346:1349–56.
 314. Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2007;56:4005–14.
 315. van der Heijde D, Dijkmans B, Geusens P, et al.; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial [ASSERT]. *Arthritis Rheum* 2005;52:582–91.
 316. van der Heijde D, Kivitz A, Schiff MH, et al.; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006;54:2136–46.
 317. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. *Am J Gastroenterol* 2006;101:311–7.
 318. Olivieri I, Cantini F, Castiglione F, et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. *Autoimmun Rev* 2014;13:822–30.
 319. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol* 2016;68:282–98.
 320. Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. *Inflamm Bowel Dis* 2014;20:213–27.
 321. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. *Clin Exp Dermatol* 2006;31:823–4.
 322. Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. *J Eur Acad Dermatol Venereol* 2007;21:408–10.

323. Callen JP, Jackson JM. Pyoderma gangrenosum: an update. *Rheum Dis Clin North Am* 2007;33:787–802, vi.
324. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. *Am J Gastroenterol* 1985;80:615–20.
325. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. *Gut* 2006;55:505–9.
326. Juillerat P, Mottet C, Pittet V, et al. Extraintestinal manifestations of Crohn's disease. *Digestion* 2007;76:141–8.
327. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. *BMJ* 2006;333:181–4.
328. Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. *Arch Dermatol* 1992;128:1060–4.
329. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. *Aliment Pharmacol Ther* 2003;17:1273–81.
330. Cohen PR. Sweet's syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. *Orphanet J Rare Dis* 2007;2:34.
331. Travis S, Innes N, Davies MG, Daneshmend T, Hughes S. Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. *Eur J Gastroenterol Hepatol* 1997;9:715–20.
332. Ytting H, Vind I, Bang D, Munkholm P. Sweet's syndrome—an extraintestinal manifestation in inflammatory bowel disease. *Digestion* 2005;72:195–200.
333. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. *Am J Clin Dermatol* 2009;10:301–12.
334. Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. *Ann Intern Med* 2016;164:10–22.
335. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2014;63:567–77.
336. Rahier JF, Buche S, Peyrin-Biroulet L, et al.; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID]. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. *Clin Gastroenterol Hepatol* 2010;8:1048–55.
337. Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2009;29:921–7.
338. Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. *Am J Gastroenterol* 2015;110:1186–96.
339. Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. *Aliment Pharmacol Ther* 2015;42:880–8.
340. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. *J Crohns Colitis* 2012;6:518–23.
341. Soh JS, Yun WJ, Kim KJ, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. *Inflamm Bowel Dis* 2015;21:832–9.
342. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. *Inflamm Bowel Dis* 2004;10:135–9.
343. Lunder AK, Hov JR, Borthne A, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. *Gastroenterology* 2016;151:660–9.e4.
344. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. *Semin Liver Dis* 2006;26:52–61.
345. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *N Engl J Med* 1997;336:691–5.
346. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. *Gastroenterology* 2003;124:889–93.
347. Sjöqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. *Anticancer Res* 2004;24:3121–7.
348. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology* 2009;50:808–14.
349. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. *Hepatology* 1999;29:1050–6.
350. Munk EM, Pedersen L, Floyd A, Nørgård B, Rasmussen HH, Sørensen HT. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. *Am J Gastroenterol* 2004;99:884–8.
351. Rasmussen HH, Fonager K, Sørensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. *Scand J Gastroenterol* 1999;34:199–201.
352. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. *Am J Gastroenterol* 2007;102:338–43.
353. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? *Gut* 2004;53:542–8.
354. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008;103:2272–80.
355. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. *Gastroenterology* 2010;139:779–87, 787.e1.
356. Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. *Aliment Pharmacol Ther* 2007;26:653–63.
357. Aggarwal A, Atreja A, Kapadia S, Lopez R, Achkar JP. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. *Inflamm Bowel Dis* 2014;20:1593–601.
358. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study. *Circ Heart Fail* 2014;7:717–22.
359. Kristensen SL, Lindhardsen J, Ahlehoff O, et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. *Europace* 2014;16:477–84.
360. Singh S, Singh H, Loftus EV Jr, et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014;12:382–93 e1: quiz e22.
361. Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. *World J Gastroenterol* 2014;20:13501–11.
362. Recommendations of the Advisory Committee on Immunization Practices [ACIP]: use of vaccines and immune globulins for persons with altered immunocompetence. *MMWR Recomm Rep* 1993;42:1–18.
363. Symmers WS. Opportunistic infections. The concept of 'opportunistic infections'. *Proc R Soc Med* 1965;58:341–6.
364. Ananthkrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. *J Crohns Colitis* 2013;7:107–12.
365. Ha CY. Risks of infection among the older inflammatory bowel disease patients. *Curr Treat Options Gastroenterol* 2014;12:283–91.
366. Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral corticosteroids and the risk of serious infections in patients with

- elderly-onset inflammatory bowel diseases. *Am J Gastroenterol* 2014;109:1795–802; quiz 1803.
367. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. *Ann Rheum Dis* 2011;70:956–60.
 368. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008;134:929–36.
 369. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. *Am J Gastroenterol* 2012;107:1051–63.
 370. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. *J Gastroenterol* 2013;48:595–600.
 371. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2011;9:30–5.
 372. Gavazzi G, Krause KH. Ageing and infection. *Lancet Infect Dis* 2002;2:659–66.
 373. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor- α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2013;108:1268–76.
 374. Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. *Aliment Pharmacol Ther* 2015;41:1227–36.
 375. Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. *Inflamm Bowel Dis* 2010;16:507–11.
 376. Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. *Gut* 2006;55:1670–1.
 377. Habib SF, Hasan MZ, Salam I. Infliximab therapy for HIV positive Crohn's disease: a case report. *J Crohns Colitis* 2009;3:302–4.
 378. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumor necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. *Rheumatology [Oxford]* 2011;50:1700–11.
 379. Gerna G, Zavattoni M, Percivalle E, Zella D, Torsellini M, Revello MG. Diagnosis of human cytomegalovirus infections in the immunocompromised host. *Clin Diagn Virol* 1996;5:181–6.
 380. de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II International Symposium on Cytomegalovirus. *Antiviral Res* 1998;39:141–62.
 381. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum* 2005;52:3403–12.
 382. Sciaudone G, Pellino G, Guadagni I, Selvaggi F. Education and imaging: gastrointestinal: herpes simplex virus-associated erythema multiforme [HAEM] during infliximab treatment for ulcerative colitis. *J Gastroenterol Hepatol* 2011;26:610.
 383. Schunter MO, Walles T, Fritz P, et al. Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections. *J Crohns Colitis* 2007;1:41–6.
 384. MacMahon E. Investigating the pregnant woman exposed to a child with a rash. *BMJ* 2012;344:e1790.
 385. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention [CDC]. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices [ACIP]. *MMWR Recomm Rep* 2010;59:1–12.
 386. Kopylov U, Levin A, Mendelson E, et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. *Aliment Pharmacol Ther* 2012;36:145–50.
 387. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. *Inflamm Bowel Dis* 2012;18:2392–403.
 388. Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. *Inflamm Bowel Dis* 2013;19:418–22.
 389. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. *J Gastroenterol Hepatol* 2010;25:1732–8.
 390. Beaugerie L, Brousse N, Bouvier AM, et al.; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009;374:1617–25.
 391. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. *Scand J Infect Dis* 1999;31:543–7.
 392. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [III]. *J Crohns Colitis* 2014;8:31–44.
 393. Egan L, D'Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [II]. *J Crohns Colitis* 2014;8:19–30.
 394. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. *World J Gastroenterol* 2006;12:6167–71.
 395. Van Kerkhove MD, Vandemaele KA, Shinde V, et al.; WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A [H1N1] infection: a global pooled analysis. *PLoS Med* 2011;8:e1001053.
 396. Naganuma M, Fujii T, Kunisaki R, et al. Incidence and characteristics of the 2009 influenza [H1N1] infections in inflammatory bowel disease patients. *J Crohns Colitis* 2013;7:308–13.
 397. Grohskopf LA, Olsen SJ, Sokolow LZ, et al.; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP]—United States, 2014–15 influenza season. *MMWR Morb Mortal Wkly Rep* 2014;63:691–7.
 398. Sciaudone G, Pellino G, Guadagni I, Somma A, D'Armiento FP, Selvaggi F. Disseminated *Cryptococcus neoformans* infection and Crohn's disease in an immunocompetent patient. *J Crohns Colitis* 2011;5:60–3.
 399. Romano M, Cuomo A, Tuccillo C, et al. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. *Dis Colon Rectum* 2007;50:650–9.
 400. Poppers DM, Scherl EJ. Prophylaxis against *Pneumocystis pneumonia* in patients with inflammatory bowel disease: toward a standard of care. *Inflamm Bowel Dis* 2008;14:106–13.
 401. Sichletidis L, Settas L, Spyros D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. *Int J Tuberc Lung Dis* 2006;10:1127–32.
 402. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345:1098–104.
 403. Abreu C, Magro F, Vilas-Boas F, Lopes S, Macedo G, Sarmiento A. *Listeria* infection in patients on anti-TNF treatment: report of two cases and review of the literature. *J Crohns Colitis* 2013;7:175–82.
 404. Committee BTSSoC. BTS recommendations for assessing risk and for managing *Mycobacterium tuberculosis* infection and disease in patients due to start anti-TNF-alpha treatment. *Thorax* 2005;60:800–5.
 405. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. *Aliment Pharmacol Ther* 2008;27:19–30.
 406. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2012;18:1042–7.
 407. Beigel F, Jürgens M, Filik L, et al. Severe *Legionella pneumophila pneumonia* following infliximab therapy in a patient with Crohn's disease. *Inflamm Bowel Dis* 2009;15:1240–4.

408. Diederer BM. Legionella spp. and Legionnaires' disease. *J Infect* 2008;56:1–12.
409. Parra MI, Martínez MC, Remacha MA, et al. Pneumonia due to *Nocardia cyriacigeorgica* in a patient with Crohn's disease treated with infliximab. *J Crohns Colitis* 2008;2:331–2.
410. Singh SM, Rau NV, Cohen LB, Harris H. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. *CMAJ* 2004;171:1063–4.
411. Abreu C, Carvalho T, Sarmento A, Magro F. Stool isolation of nocardia nova in two immunomodulated patients with inflammatory bowel diseases. *J Clin Gastroenterol* 2016;50:92.
412. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with *Clostridium difficile*-associated disease. *Am J Gastroenterol* 2010;105:2040–9.
413. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant *Clostridium difficile* colitis during an epidemic caused by a hypervirulent strain. *Ann Surg* 2007;245:267–72.
414. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis* 2014;8:1569–81.
415. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of *Clostridium difficile* in adults: a systematic review. *JAMA* 2015;313:398–408.
416. Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med* 2011;364:422–31.
417. Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of *Clostridium difficile* infection in patients with inflammatory bowel disease: the RECIDIVISM study. *Am J Gastroenterol* 2016;111:1141–6.
418. Hill DR, Ericsson CD, Pearson RD, et al.; Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1499–539.
419. Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I, et al. Immunogenicity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17:1117–24.
420. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. *Int J Gynaecol Obstet* 1997;58:229–37.
421. Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;38:847–53.
422. Mañosa M, Navarro-Llavat M, Marín L, Zabana Y, Cabré E, Domènech E. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. *Scand J Gastroenterol* 2013;48:427–32.
423. Selinger CP, Ghorayeb J, Madill A. What factors might drive voluntary childlessness [VC] in women with IBD? does IBD-specific pregnancy-related knowledge matter? *J Crohns Colitis* 2016;10:1151–8.
424. McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. *Inflamm Bowel Dis* 2016;22:213–23.
425. Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. *Gut* 1981;22:452–5.
426. O'Moráin C, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. *Gut* 1984;25:1078–84.
427. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. *Arch Dermatol* 1980;116:215–7.
428. Sands K, Jansen R, Zaslaw S, Greenwald D. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. *Aliment Pharmacol Ther* 2015;41:821–34.
429. Davies RJ, O'Connor BI, Victor C, MacRae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. *Dis Colon Rectum* 2008;51:1032–5.
430. Damgaard B, Wettergren A, Kirkegaard P. Social and sexual function following ileal pouch-anal anastomosis. *Dis Colon Rectum* 1995;38:286–9.
431. Pabby V, Oza SS, Dodge LE, et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastomosis. *Am J Gastroenterol* 2015;110:792–7.
432. Pedersen N, Bortoli A, Duricova D, et al.; European Crohns and Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. *Aliment Pharmacol Ther* 2013;38:501–12.
433. de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. *Am J Gastroenterol* 2016;111:1305–12.
434. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. *Inflamm Bowel Dis* 2011;17:795–801.
435. Lin HC, Chiu CC, Chen SF, Lou HY, Chiu WT, Chen YH. Ulcerative colitis and pregnancy outcomes in an Asian population. *Am J Gastroenterol* 2010;105:387–94.
436. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013;11:286–92; quiz e24.
437. Zelinkova Z, van der Ent C, Bruin KF, et al.; Dutch Delta IBD Group. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. *Clin Gastroenterol Hepatol* 2013;11:318–21.
438. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. *Gastroenterology* 2007;133:1106–12.
439. Bortoli A, Pedersen N, Duricova D, et al.; European Crohns and Colitis Organisation [ECCO] Study Group of Epidemiologic Committee [EpiCom]. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. *Aliment Pharmacol Ther* 2011;34:724–34.
440. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. *Nat Rev Gastroenterol Hepatol* 2014;11:116–27.
441. Jharap B, de Boer NK, Stokkers P, et al.; Dutch Initiative on Crohn and Colitis. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. *Gut* 2014;63:451–7.
442. Lewden B, Vial T, Elefant E, Nelva A, Carlier P, Descotes J; French Network of Regional Pharmacovigilance Centers. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. *J Rheumatol* 2004;31:2360–5.
443. de Meij TG, Jharap B, Kneepkens CM, van Bodegraven AA, de Boer NK; Dutch Initiative on Crohn and Colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;38:38–43.
444. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. *Gastroenterology* 2016;151:110–9.
445. Korelitz BI. Inflammatory bowel disease and pregnancy. *Gastroenterol Clin North Am* 1998;27:213–24.
446. Hernández-Díaz S, Su YC, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates among women of childbearing age. *Reprod Toxicol* 2013;37:1–5.
447. Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. *Int J Occup Med Environ Health* 2011;24:115–41.
448. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. *Reprod Toxicol* 2008;25:271–5.
449. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. *Am J Gastroenterol* 2008;103:1203–9.
450. Visser BC, Glasgow RE, Mulvihill KK, Mulvihill SJ. Safety and timing of nonobstetric abdominal surgery in pregnancy. *Dig Surg* 2001;18:409–17.

451. Hill J, Clark A, Scott NA. Surgical treatment of acute manifestations of Crohn's disease during pregnancy. *J R Soc Med* 1997;90:64–6.
452. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalazine in human pregnancy: a prospective controlled cohort study. *Gastroenterology* 1998;114:23–8.
453. Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. *Aliment Pharmacol Ther* 1998;12:1101–8.
454. Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. *J Crohns Colitis* 2011;5:95–100.
455. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. *J Pediatr* 1972;81:936–45.
456. Ost L, Wettrell G, Björkhem I, Rane A. Prednisolone excretion in human milk. *J Pediatr* 1985;106:1008–11.
457. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis* 2011;5:555–8.
458. Quan WL, Chia CK, Yim HB. Safety of endoscopic procedures during pregnancy. *Singapore Med J* 2006;47:525–8.
459. Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. *Dig Dis Sci* 1996;41:2353–61.
460. de Lima A, Zelinkova Z, van der Woude CJ. A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. *J Crohns Colitis* 2015;9:519–24.
461. Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. *Br J Clin Pharmacol* 1990;30:787–93.
462. Nitsun M, Szokol JW, Saleh HJ, et al. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. *Clin Pharmacol Ther* 2006;79:549–57.
463. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;48:526–35.
464. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012;10:639–45.
465. Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. *Am J Gastroenterol* 2013;108:1869–76.
466. Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. *Am J Gastroenterol* 2015;110:1022–34.
467. Selinger CP, Andrews JM, Titman A, et al.; Sydney IBD Cohort Study Group. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2014;12:644–50.
468. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. *Clin Gastroenterol Hepatol* 2004;2:1088–95.
469. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. *Gut* 2008;57:1246–51.
470. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. *Gastroenterology* 2013;145:166–75.e8.
471. Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. *Inflamm Bowel Dis* 2003;9:351–5.
472. Choi CH, Ignjatovic-Wilson A, Askari A, et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. *Am J Gastroenterol* 2015;110:1461–71; quiz 1472.
473. Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. *Inflamm Bowel Dis* 2009;15:1331–6.
474. Bergeron V, Vienne A, Sokol H, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. *Am J Gastroenterol* 2010;105:2405–11.
475. Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? *Gut* 2001;48:430–4.
476. Jørgensen KK, Lindström L, Cvanarova M, et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. *Scand J Gastroenterol* 2012;47:1021–9.
477. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. *Clin Gastroenterol Hepatol* 2014;12:265–73.e1.
478. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. *Gastroenterology* 2006;130:1941–9.
479. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. *Gastroenterology* 1998;115:1079–83.
480. Koutroubakis IE, Regueiro M, Schoen RE, et al. Multiyear patterns of serum inflammatory biomarkers and risk of colorectal neoplasia in patients with ulcerative colitis. *Inflamm Bowel Dis* 2016;22:100–5.
481. Löfberg R, Broström O, Karlén P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis—a 15-year follow-up study. *Gastroenterology* 1990;99:1021–31.
482. Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. *Br J Cancer* 2009;101:1671–5.
483. Karlén P, Kornfeld D, Broström O, Löfberg R, Persson PG, Ekbohm A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. *Gut* 1998;42:711–4.
484. Eaden J, Abrams K, Ekbohm A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000;14:145–53.
485. Cairns SR, Scholefield JH, Steele RJ, et al.; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups [update from 2002]. *Gut* 2010;59:666–89.
486. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology* 2006;130:1030–8.
487. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? *Lancet* 1994;343:71–4.
488. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. *Inflamm Bowel Dis* 2006;12:669–76.
489. Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. *Dis Colon Rectum* 2002;45:615–20.
490. Leidenius M, Kellokumpu I, Husa A, Riihelä M, Sipponen P. Dysplasia and carcinoma in longstanding ulcerative colitis: an endoscopic and histological surveillance programme. *Gut* 1991;32:1521–5.
491. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. *Aliment Pharmacol Ther* 2007;25:657–68.
492. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. *Gut* 2003;52:1127–32.
493. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. *Gastrointest Endosc* 2004;60:334–9.

494. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 2002;56:48–54.
495. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. *Hum Pathol* 1989;20:1008–14.
496. Thomas-Gibson S, Rogers P, Cooper S, et al. Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. *Endoscopy* 2006;38:456–60.
497. Subramanian V, Ramappa V, Telakis E, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. *Inflamm Bowel Dis* 2013;19:350–5.
498. Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. *Gastroenterology* 2016;151:1122–30.
499. Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. *Eur J Gastroenterol Hepatol* 2011;23:680–9.
500. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. *Gastroenterology* 2003;124:880–8.
501. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. *Endoscopy* 2005;37:1186–92.
502. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. *Gastroenterology* 2007;132:874–82.
503. Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. *Aliment Pharmacol Ther* 2011;33:304–12.
504. Wu L, Li P, Wu J, Cao Y, Gao F. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. *Colorectal Dis* 2012;14:416–20.
505. Carballal S, Maisterra S, Lopez-Serrano A, et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. *Gut* 2016, 9 September. doi:10.1136/gutjnl-2016-312332.
506. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. *Endoscopy* 2007;39:216–21.
507. Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. *Am J Gastroenterol* 2012;107:885–90.
508. Pellisé M, López-Cerón M, Rodríguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. *Gastrointest Endosc* 2011;74:840–8.
509. Günther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. *Int J Colorectal Dis* 2011;26:667–72.
510. van den Broek FJ, van Es JA, van Eeden S, et al. Pilot study of probe-based confocal laser endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis. *Endoscopy* 2011;43:116–22.
511. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. *Gastroenterology* 1997;112:29–32.
512. Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. *Dis Colon Rectum* 2001;44:77–85.
513. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. *Eur J Gastroenterol Hepatol* 1996;8:1179–83.
514. Pinczowski D, Ekblom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. *Gastroenterology* 1994;107:117–20.
515. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? *Am J Gastroenterol* 2003;98:2784–8.
516. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicilate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. *Clin Gastroenterol Hepatol* 2006;4:1346–50.
517. Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. *Am J Gastroenterol* 2007;102:829–36.
518. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. *Gut* 2005;54:1573–8.
519. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:367–71.
520. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. *Am J Gastroenterol* 2011;106:731–6.
521. Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. *Am J Gastroenterol* 2012;107:1298–304; quiz 1297, 1305.
522. Beaugerie L, Seksik P, Bouvier AM, et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME cohort. *Gastroenterology* 2009;136:A-54.
523. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. *Gastroenterology* 2004;126:1634–48.
524. Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. *Aliment Pharmacol Ther* 2010;31:202–9.
525. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. *Clin Gastroenterol Hepatol* 2008;6:1225–30; quiz 1177.
526. Bergeron V, Nion-Larmurier I, Vienne A, et al. Azathioprine [AZA] is associated with less histological inflammation of the colon in inactive IBD. *Gastroenterology* 2010;138:S-693.
527. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Ann Intern Med* 2001;134:89–95.
528. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. *Clin Gastroenterol Hepatol* 2005;3:1015–21.
529. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. *Gut* 2012;61:235–40.
530. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. *Clin Gastroenterol Hepatol* 2014;12:1793–800. e1.
531. Bourrier A, Carrat F, Colombel JF, et al.; CESAME study group. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Aliment Pharmacol Ther* 2016;43:252–61.
532. Lopez A, Mounier M, Bouvier AM, et al.; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syn-

- dromes in patients who received thiopurine treatment for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2014;12:1324–9.
533. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al.; Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology* 2011;141:1621–28.e1–5.
 534. Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2013;19:1631–8.
 535. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonial indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. *Gut* 2004;53:256–60.
 536. Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. *Am J Gastroenterol* 1999;94:1746–50.
 537. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* 1983;14:931–68.
 538. Goldman H. Significance and detection of dysplasia in chronic colitis. *Cancer* 1996;78:2261–3.
 539. Odze RD, Goldblum J, Noffsinger A, Alsaigh N, Rybicki LA, Fogt F. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. *Mod Pathol* 2002;15:379–86.
 540. Eaden J, Abrams K, McKay H, Denley H, Mayberry J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. *J Pathol* 2001;194:152–7.
 541. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology* 2015;148:639–51.e28.
 542. Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or mass [DALM] detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. *Gastroenterology* 1981;80:366–74.
 543. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. *Gut* 1990;31:800–6.
 544. Butt JH, Konishi F, Morson BC, Lennard-Jones JE, Ritchie JK. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. *Dig Dis Sci* 1983;28:18–26.
 545. Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. *Gut* 2006;55:1151–5.
 546. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. *Am J Surg Pathol* 1998;22:275–84.
 547. Suzuki K, Muto T, Shinozaki M, Yokoyama T, Matsuda K, Masaki T. Differential diagnosis of dysplasia-associated lesion or mass and coincidental adenoma in ulcerative colitis. *Dis Colon Rectum* 1998;41:322–7.
 548. Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. *Clin Gastroenterol Hepatol* 2004;2:534–41.
 549. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. *Gastroenterology* 1999;117:1295–300.
 550. Wanders LK, Dekker E, Pullens B, Bassett P, Travis SP, East JE. Cancer risk after resection of polypoid dysplasia in patients with long-standing ulcerative colitis: a meta-analysis. *Clin Gastroenterol Hepatol* 2014;12:756–64.
 551. Siegel CA, Schwartz LM, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. *Inflamm Bowel Dis* 2010;16:1658–62.
 552. Engelsjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. *Gastroenterology* 1999;117:1288–94; discussion 1488–91.
 553. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. *Gastroenterology* 2003;125:1311–9.
 554. Berndtsson I, Lindholm E, Ekman I. Thirty years of experience living with a continent ileostomy: bad restrooms—not my reservoir—decide my life. *J Wound Ostomy Continence Nurs* 2005;32:321–6; quiz 327–8.
 555. Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. *Colorectal Dis* 2001;3:223–6.
 556. Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis—a prospective study. *Colorectal Dis* 2003;5:173–9.
 557. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. *Br J Surg* 2010;97:404–9.
 558. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. *J Am Coll Surg* 2003;197:379–85.
 559. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. *Am J Surg* 2002;184:45–51.
 560. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. *Dis Colon Rectum* 2005;48:70–3.
 561. Bartels SA, Gardenbroek TJ, Bos L, et al. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. *Colorectal Dis* 2013;15:1392–8.
 562. Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J, Pemberton JH, Cima RR. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? *Dis Colon Rectum* 2009;52:187–92.
 563. Marceau C, Alves A, Ouaiissi M, Bouhnik Y, Valleur P, Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. *Surgery* 2007;141:640–4.
 564. McKee RF, Keenan RA, Munro A. Colectomy for acute colitis: is it safe to close the rectal stump? *Int J Colorectal Dis* 1995;10:222–4.
 565. Carter FM, McLeod RS, Cohen Z. Subtotal colectomy for ulcerative colitis: complications related to the rectal remnant. *Dis Colon Rectum* 1991;34:1005–9.
 566. Annibaldi R, Oresland T, Hultén L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? *Dis Colon Rectum* 1994;37:321–9.
 567. Lovegrove RE, Constantinides VA, Heriot AG, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis [IPAA] following proctocolectomy: a meta-analysis of 4183 patients. *Ann Surg* 2006;244:18–26.
 568. Kirat HT, Remzi FH, Kiran RP, Fazio VW. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. *Surgery* 2009;146:723–9; discussion 729–30.
 569. Heppell J, Weiland LH, Perrault J, Pemberton JH, Telander RL, Beart RW Jr. Fate of the rectal mucosa after rectal mucosectomy and ileoanal anastomosis. *Dis Colon Rectum* 1983;26:768–71.
 570. Al-Sukhni W, McLeod RS, MacRae H, O'Connor B, Huang H, Cohen Z. Oncologic outcome in patients with ulcerative colitis associated with dysplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. *Dis Colon Rectum* 2010;53:1495–500.
 571. Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, Ten Kate FJ, Bemelman WA. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. *Br J Surg* 2007;94:534–45.
 572. Börjesson L, Willén R, Haboubi N, Duff SE, Hultén L. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. *Colorectal Dis* 2004;6:494–8.
 573. Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. *Ann Surg* 2001;234:788–94.

574. García-Botello SA, García-Armengol J, García-Granero E, et al. A prospective audit of the complications of loop ileostomy construction and takedown. *Dig Surg* 2004;21:440–6.
575. Weston-Petrides GK, Lovegrove RE, Tilney HS, et al. Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. *Arch Surg* 2008;143:406–12.
576. Hainsworth PJ, Bartolo DC. Selective omission of loop ileostomy in restorative proctocolectomy. *Int J Colorectal Dis* 1998;13:119–23.
577. Galandiuk S, Wolff BG, Dozois RR, Beart RW Jr. Ileal pouch-anal anastomosis without ileostomy. *Dis Colon Rectum* 1991;34:870–3.
578. Gignoux BM, Dehni N, Parc R, Tiret E. Ileal pouch anal-anastomosis without protective ileostomy. *Gastroenterol Clin Biol* 2002;26:671–4.
579. Lovegrove RE, Tilney HS, Remzi FH, Nicholls RJ, Fazio VW, Tekkis PP. To divert or not to divert: a retrospective analysis of variables that influence ileostomy omission in ileal pouch surgery. *Arch Surg* 2011;146:82–8.
580. Tekkis PP, Fazio VW, Lavery IC, et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. *Ann Surg* 2005;241:262–8.
581. Burns EM, Bottle A, Aylin P, et al. Volume analysis of outcome following restorative proctocolectomy. *Br J Surg* 2011;98:408–17.
582. Raval MJ, Schnitzler M, O'Connor BI, Cohen Z, McLeod RS. Improved outcome due to increased experience and individualized management of leaks after ileal pouch-anal anastomosis. *Ann Surg* 2007;246:763–70.
583. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. *Ann Surg* 2003;238:229–34.
584. Karoui M, Cohen R, Nicholls J. Results of surgical removal of the pouch after failed restorative proctocolectomy. *Dis Colon Rectum* 2004;47:869–75.
585. Börjesson L, Oresland T, Hultén L. The failed pelvic pouch: conversion to a continent ileostomy. *Tech Coloproctol* 2004;8:102–5.
586. Baixauli J, Delaney CP, Wu JS, Remzi FH, Lavery IC, Fazio VW. Functional outcome and quality of life after repeat ileal pouch-anal anastomosis for complications of ileoanal surgery. *Dis Colon Rectum* 2004;47:2–11.
587. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. *Ann Surg* 1995;222:120–7.
588. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. *Gastroenterology* 1994;107:1856–60.
589. Magro F, Lopes S, Rodrigues S, Azevedo I. How to manage pouchitis in ulcerative colitis? *Curr Drug Targets* 2011;12:1454–61.
590. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. *Arch Surg* 1996;131:497–500; discussion 501–2.
591. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. *Br J Surg* 1998;85:800–3.
592. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. *Gut* 1996;38:234–9.
593. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. *World J Surg* 2000;24:851–6.
594. Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. *Am J Gastroenterol* 2005;100:93–101.
595. Berndtsson I, Oresland T, Hultén L. Sexuality in patients with ulcerative colitis before and after restorative proctocolectomy: a prospective study. *Scand J Gastroenterol* 2004;39:374–9.
596. Olsen KO, Joellson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. *Br J Surg* 1999;86:493–5.
597. Ørding Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. *Gastroenterology* 2002;122:15–9.
598. Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. *Surgery* 2004;136:795–803.
599. Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. *Dis Colon Rectum* 2004;47:1119–26.
600. Oresland T, Palmblad S, Ellström M, Berndtsson I, Crona N, Hultén L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. *Int J Colorectal Dis* 1994;9:77–81.
601. Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. *Ann Surg* 2013;258:275–82.
602. Bartels SA, Vlug MS, Henneman D, Ponsioen CY, Tanis PJ, Bemelman WA. Less adhesiolysis and hernia repair during completion proctocolectomy after laparoscopic emergency colectomy for ulcerative colitis. *Surg Endosc* 2012;26:368–73.
603. Indar AA, Young-Fadok TM, Heppell J, et al. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. *World J Surg* 2009;33:1049–52.
604. Bartels SA, D'Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. *Ann Surg* 2012;256:1045–8.
605. Mortier PE, Gambiez L, Karoui M, et al. Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. *Gastroenterol Clin Biol* 2006;30:594–7.
606. Olsen KØ, Juul S, Bülow S, et al. Female fecundity before and after operation for familial adenomatous polyposis. *Br J Surg* 2003;90:227–31.
607. Börjesson L, Lundstam U, Oresland T, Brevinge H, Hultén L. The place for colectomy and ileorectal anastomosis: a valid surgical option for ulcerative colitis? *Tech Coloproctol* 2006;10:237–41; discussion 241.
608. da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. *Br J Surg* 2010;97:65–9.
609. Doeksen A, Gooszen JA, van Duijvendijk P, et al. Sexual and urinary functioning after rectal surgery: a prospective comparative study with a median follow-up of 8.5 years. *Int J Colorectal Dis* 2011;26:1549–57.
610. Zetterström J, López A, Holmström B, et al. Obstetric sphincter tears and anal incontinence: an observational follow-up study. *Acta Obstet Gynecol Scand* 2003;82:921–8.
611. Walsh CJ, Mooney EF, Upton GJ, Motson RW. Incidence of third-degree perineal tears in labour and outcome after primary repair. *Br J Surg* 1996;83:218–21.
612. Snooks SJ, Swash M, Mathers SE, Henry MM. Effect of vaginal delivery on the pelvic floor: a 5-year follow-up. *Br J Surg* 1990;77:1358–60.
613. Snooks SJ, Setchell M, Swash M, Henry MM. Injury to innervation of pelvic floor sphincter musculature in childbirth. *Lancet* 1984;2:546–50.
614. Hahnloser D, Pemberton JH, Wolff BG, et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. *Dis Colon Rectum* 2004;47:1127–35.
615. Remzi FH, Gorgun E, Bast J, et al. Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. *Dis Colon Rectum* 2005;48:1691–9.
616. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. *Dis Colon Rectum* 2007;50:1128–38.
617. Polle SW, Vlug MS, Slors JF, et al. Effect of vaginal delivery on long-term pouch function. *Br J Surg* 2006;93:1394–401.
618. Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, Weiss EG, Wexner SD. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? *Colorectal Dis* 2011;13:177–83.
619. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? *Arch Surg* 2005;140:534–9; discussion 539–40.
620. Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. *Aust N Z J Surg* 2000;70:906–7.

621. Delaney CP, Dadvand B, Remzi FH, Church JM, Fazio VW. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. *Dis Colon Rectum* 2002;45:890-4; discussion 894.
622. Kiran RP, El-Gazzaz G, Remzi FH, et al. Influence of age at ileoanal pouch creation on long-term changes in functional outcomes. *Colorectal Dis* 2011;13:184-90.
623. Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. *Dig Dis* 1997;15:172-88.
624. Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. *Gastroenterology* 2001;121:261-7.
625. Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation [cuffitis] in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. *Am J Gastroenterol* 2004;99:1527-31.
626. Leijonmarck CE, Löfberg R, Ost A, Hellers G. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. *Dis Colon Rectum* 1990;33:195-200.
627. Lepistö A, Järvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. *Scand J Surg* 2005;94:40-2.
628. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. *Dig Surg* 2005;22:69-79.
629. Sagar PM, Dozois RR, Wolff BG, Kelly KA. Disconnection, pouch revision and reconnection of the ileal pouch-anal anastomosis. *Br J Surg* 1996;83:1401-5.
630. Prudhomme M, Dehni N, Dozois RR, Turet E, Parc R. Causes and outcomes of pouch excision after restorative proctocolectomy. *Br J Surg* 2006;93:82-6.
631. MacLean AR, Cohen Z, MacRae HM, et al. Risk of small bowel obstruction after the ileal pouch-anal anastomosis. *Ann Surg* 2002;235:200-6.
632. Fonkalsrud EW, Bustorff-Silva J. Reconstruction for chronic dysfunction of ileoanal pouches. *Ann Surg* 1999;229:197-204.
633. Sagar PM, Pemberton JH. Intraoperative, postoperative and reoperative problems with ileoanal pouches. *Br J Surg* 2012;99:454-68.
634. Herbst F, Sieleznoff I, Nicholls RJ. Salvage surgery for ileal pouch outlet obstruction. *Br J Surg* 1996;83:368-71.
635. Maconi G, Tonolini M, Monteleone M, et al. Transperineal perineal ultrasound versus magnetic resonance imaging in the assessment of perianal Crohn's disease. *Inflamm Bowel Dis* 2013;19:2737-43.
636. McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis PP, Ciclitira PJ, Nicholls RJ. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. *Inflamm Bowel Dis* 2009;15:1256-63.
637. Broder JC, Tkacz JN, Anderson SW, Soto JA, Gupta A. Ileal pouch-anal anastomosis surgery: imaging and intervention for post-operative complications. *Radiographics* 2010;30:221-33.
638. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. *Inflamm Bowel Dis* 2009;15:1062-70.
639. Lake JP, Firoozmand E, Kang JC, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. *J Gastrointest Surg* 2004;8:547-51.
640. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. *Gastroenterology* 2003;125:320-7.
641. Mahadevan U, Loftus EV Jr, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. *Inflamm Bowel Dis* 2002;8:311-6.
642. Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. *Am J Gastroenterol* 2008;103:2373-81.
643. Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. *Br J Surg* 2006;93:793-9.
644. Zmora O, Khaikin M, Pishori T, et al. Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? *Int J Colorectal Dis* 2007;22:289-92.
645. Patton D, Gupta N, Wojcicki JM, Garnett EA, Nobuhara K, Heyman MB. Postoperative outcome of colectomy for pediatric patients with ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2010;51:151-4.
646. Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. *J Pediatr Surg* 2007;42:31-4; discussion 34-5.
647. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. *Aliment Pharmacol Ther* 2016;43:705-16.
648. Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: preoperative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2010;31:486-92.
649. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology* 2005;128:1805-11.
650. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. *J Am Coll Surg* 2007;204:956-62; discussion 962-3.
651. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? *Dis Colon Rectum* 2007;50:1747-53.
652. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of post-operative complications after restorative proctocolectomy. *Dis Colon Rectum* 2008;51:1202-7; discussion 1207-10.
653. Coquet-Reinier B, Berdah SV, Grimaud JC, et al. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. *Surg Endosc* 2010;24:1866-71.
654. Bordeianou L, Kunitake H, Shellito P, Hodin R. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. *Int J Colorectal Dis* 2010;25:401-4.
655. Rizzo G, Armuzzi A, Pugliese D, et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. *Int J Colorectal Dis* 2011;26:1435-44.
656. Eshuis EJ, Al Saady RL, Stokkers PC, Ponsioen CY, Tanis PJ, Bemelman WA. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. *J Crohns Colitis* 2013;7:142-9.
657. Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Preoperative use of anti-TNF- α agents and the risk of post-operative complications in patients with Crohn's disease—a nationwide cohort study. *Aliment Pharmacol Ther* 2013;37:214-24.
658. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. *Gut* 2010;59:49-54.
659. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. *J Crohns Colitis* 2008;2:219-25.
660. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. *Gastroenterology* 2009;137:1250-60; quiz 1520.
661. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. *Clin Gastroenterol Hepatol* 2008;6:1112-6.
662. Leblanc S, Allez M, Seksik P, et al.; GETAID. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. *Am J Gastroenterol* 2011;106:771-7.

663. Mañosa M, López San Román A, Garcia-Planella E, et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. *Digestion* 2009;80:30–5.
664. Ståhlberg D, Gullberg K, Liljeqvist L, Hellers G, Löfberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. *Dis Colon Rectum* 1996;39:1012–8.
665. Svanninger G, Nordgren S, Oresland T, Hultén L. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. *Scand J Gastroenterol* 1993;28:695–700.
666. Penna C, Turet E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. *Br J Surg* 1993;80:765–7.
667. Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. *Am J Surg* 1993;165:322–5.
668. Dozois RR, Goldberg SM, Rothenberger DA, et al. Restorative proctocolectomy with ileal reservoir. *Int J Colorectal Dis* 1986;1:2–19.
669. Marcello PW, Roberts PL, Schoetz DJ Jr, Coller JA, Murray JJ, Veidenheimer MC. Long-term results of the ileoanal pouch procedure. *Arch Surg* 1993;128:500–3; discussion 503–4.
670. Tytgat GN, van Deventer SJ. Pouchitis. *Int J Colorectal Dis* 1988;3:226–8.
671. Pemberton JH. The problem with pouchitis. *Gastroenterology* 1993;104:1209–11.
672. Shepherd NA, Hultén L, Tytgat GN, et al. Pouchitis. *Int J Colorectal Dis* 1989;4:205–29.
673. Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. *Am J Gastroenterol* 2002;97:972–7.
674. Pardi DS, Shen B. Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. *Endoscopy* 2008;40:529–33.
675. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. *Int J Colorectal Dis* 1986;1:167–74.
676. Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. *J Clin Pathol* 1987;40:601–7.
677. Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. *Int J Colorectal Dis* 1998;13:103–7.
678. Shepherd NA, Healey CJ, Warren BF, Richman PI, Thomson WH, Wilkinson SP. Distribution of mucosal pathology and an assessment of colonic neotypic change in the pelvic ileal reservoir. *Gut* 1993;34:101–5.
679. Ruselevan Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? *Gut* 1994;35:658–64.
680. Biancone L, Palmieri G, Lombardi A, et al. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. *Am J Gastroenterol* 2003;98:2719–26.
681. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. *Aliment Pharmacol Ther* 2006;23:1087–96.
682. Shen B, Fazio VW, Remzi FH, et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. *Clin Gastroenterol Hepatol* 2006;4:81–9; quiz 2–3.
683. Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. *Clostridium difficile*-associated pouchitis. *Dig Dis Sci* 2006;51:2361–4.
684. Bell AJ, Price AB, Forbes A, Ciclitira PJ, Groves C, Nicholls RJ. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. *Colorectal Dis* 2006;8:402–10.
685. Shen B, Fazio VW, Remzi FH, et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. *Dig Dis Sci* 2007;52:3321–8.
686. Landy J, Al-Hassi HO, McLaughlin SD, et al. Etiology of pouchitis. *Inflamm Bowel Dis* 2012;18:1146–55.
687. Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. *Ann Surg* 1998;227:654–62; discussion 663–5.
688. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. *Ann Surg* 1990;211:622–7; discussion 627–9.
689. Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. *Clin Gastroenterol Hepatol* 2005;3:60–6.
690. Carter MJ, Di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. *Gastroenterology* 2001;121:805–11.
691. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody [pANCA] in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. *Gut* 2001;49:671–7.
692. Shen B, Sanmiguel C, Bennett AE, et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. *Inflamm Bowel Dis* 2011;17:994–1002.
693. Lipman JM, Kiran RP, Shen B, Remzi F, Fazio VW. Perioperative factors during ileal pouch-anal anastomosis predict pouchitis. *Dis Colon Rectum* 2011;54:311–7.
694. Sandborn W. *Pouchitis: risk factors, frequency, natural history, classification and public health perspective*. In: *Trends in Inflammatory Bowel Disease* 1996. Lancaster, UK: Kluwer Academic Publishers; 1997: 51–63.
695. Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. *Inflamm Bowel Dis* 2009;15:1424–31.
696. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis* 2001;7:301–5.
697. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. *Mayo Clin Proc* 1994;69:409–15.
698. Evgenikos N, Bartolo DC, Hamer-Hodges DW, Ghosh S. Comparison of the Moskowitz criteria and the pouchitis disease activity index [PDAI] for diagnosis of ileoanal pouch inflammation. *Colorectal Dis* 2001;3:161–4.
699. Heuschen UA, Allemeyer EH, Hinz U, et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. *Dis Colon Rectum* 2002;45:776–86; discussion 786–8.
700. Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. *Am J Gastroenterol* 2005;100: 2796–807.
701. Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. *Cochrane Database Syst Rev* 2000;CD001176.
702. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. *Dig Dis Sci* 1994;39:1193–6.
703. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal-pouch anal anastomosis for ulcerative colitis. *Cochrane Database Syst Rev* 2010;6:CD001176.
704. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. *Aliment Pharmacol Ther* 2007;25:1231–6.
705. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. *Dis Colon Rectum* 2007;50:498–508.
706. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. *Aliment Pharmacol Ther* 1999;13:713–8.
707. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. *Colorectal Dis* 2005;7:182–6.
708. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. *Aliment Pharmacol Ther* 2002;16:909–17.
709. Navaneethan U, Venkatesh PG, Bennett AE, et al. Impact of budesonide on liver function tests and gut inflammation in patients with primary

- sclerosing cholangitis and ileal pouch anal anastomosis. *J Crohns Colitis* 2012;**6**:536–42.
710. Gionchetti P, Calabrese C, Calafiore A, *et al.* Oral beclomethasone dipropionate in chronic refractory pouchitis. *J Crohns Colitis* 2014;**8**:649–53.
711. Sambuelli A, Boerr L, Negreira S, *et al.* Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial. *Aliment Pharmacol Ther* 2002;**16**:27–34.
712. Winter TA, Dalton HR, Merrett MN, Campbell A, Jewell DP. Cyclosporin A retention enemas in refractory distal ulcerative colitis and ‘pouchitis’. *Scand J Gastroenterol* 1993;**28**:701–4.
713. de Silva HJ, Ireland A, Kettlewell M, Mortensen N, Jewell DP. Short-chain fatty acid irrigation in severe pouchitis. *N Engl J Med* 1989;**321**:1416–7.
714. Tremaine W, Sandborn W, Phillips SF, *et al.* Short-chain fatty acid [SCFA] enema therapy for treatment-resistant pouchitis following ileal pouch-anal anastomosis [IPAA] for ulcerative colitis. *Gastroenterology* 1999;**106**:A784.
715. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. *Mayo Clin Proc* 1993;**68**:978–81.
716. Ferrante M, D’Haens G, Dewit O, *et al.* Efficacy of infliximab in refractory pouchitis and Crohn’s disease-related complications of the pouch: a Belgian case series. *Inflamm Bowel Dis* 2010;**16**:243–9.
717. Calabrese C, Gionchetti P, Rizzello F, *et al.* Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. *Aliment Pharmacol Ther* 2008;**27**:759–64.
718. Barreiro-de Acosta M, Garcia-Bosch O, Souto R, *et al.* Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. *Inflamm Bowel Dis* 2012;**18**:812–7.
719. Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, *et al.* Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. *Eur J Gastroenterol Hepatol* 2012;**24**:756–8.
720. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. *Aliment Pharmacol Ther* 2004;**19**:281–6.
721. Uchino M, Ikeuchi H, Matsuoka H, *et al.* Topical tacrolimus therapy for antibiotic-refractory pouchitis. *Dis Colon Rectum* 2013;**56**:1166–73.
722. Gionchetti P, Rizzello F, Venturi A, *et al.* Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000;**119**:305–9.
723. Mimura T, Rizzello F, Helwig U, *et al.* Once daily high dose probiotic therapy [VSL#3] for maintaining remission in recurrent or refractory pouchitis. *Gut* 2004;**53**:108–14.
724. Singh S, Stroud AM, Holubar SD, *et al.* Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database Syst Rev* 2015;Cd001176.
725. Gionchetti P, Rizzello F, Helwig U, *et al.* Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003;**124**:1202–9.